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Abstract
This article presents updated diagnostic and therapeutic guidelines for the management of pancreatic neuroendocrine tumours (PNEN), 
proposed by the Polish Network of Neuroendocrine Tumours. The guidelines contain new data received in the years 2013–2016, which 
confirm previous recommendations, and have led to modification of previous guidelines or have resulted in the formulation of new 
guidelines. Biochemical and imaging (anatomical and functional) tests are of great importance in diagnostics, as well as histopathological 
diagnosis to determine the management of PNEN patients, but they must be confirmed by an immunohistochemical examination. PNEN 
therapy requires collaboration among members of a multidisciplinary of specialists experienced in the management of these neoplasms. 
Surgery is the basic form of treatment in many cases. Further therapy requires a multidirectional procedure; therefore, the rules of bio-
therapy, peptide receptor radionuclide therapy, molecular targeted therapy, and chemotherapy are discussed.
(Endokrynol Pol 2017; 68 (2): 169–197)
Key words: pancreatic neuroendocrine neoplasms; functional; non-functional; diagnostics; therapy; guidelines
Pancreatic neuroendocrine neoplasms 
(excluding gastrinomas)
1.1. Epidemiology, clinical characteristics,  
and prognosis/survival
The incidence rate of pancreatic neuroendocrine neo-
plasms (PNEN) or pancreatic neuroendocrine tumours 
(PNET), both functional (F-PNET/PNEN) and non-
functional (NF-PNET/PNEN), is constantly increasing, 
and is currently approximately 0.32/100,000 people/ 
/year. PNENs account for approximately 30% of all 
gastro-entero-pancreatic neoplasms (GEP NENs). Of 
all pancreatic neuroendocrine tumours 60–90% are non-
functional, usually detected in the advanced stages, 
due to their slow growth and often asymptomatic or 
minimally symptomatic character [1–6].
Despite the lack of symptoms of hormonal hyper-
secretion, they are able to produce certain substances, 
e.g. pancreatic polypeptide (PP), chromogranin A 
(CgA), neuron-specific enolase (NSE), β-hCG subunit, 
calcitonin, neurotensin, and other peptides.
Other PNENs demonstrate hormonal activity (func-
tional tumours), which is reflected in the corresponding 
clinical symptoms [6–8].
The most commonly described F-PNETs include 
[7, 9]:
 — insulinoma — secreting insulin, and
 — gastrinoma — secreting gastrin.
 — The well-documented (> 100 cases) rare functional 
tumours (RFT) of the pancreas comprise:
 — glucagonoma — secreting glucagon,
 — VIPoma — secreting vasoactive intestinal peptide,
 — somatostatinoma — secreting somatostatin,
 — GHRHoma — secreting GHRH — (Growth-Hor-
mone-Releasing Hormone),
 — ACTHoma — secreting ACTH — corticotropin,
 — PNET causing carcinoid syndrome — secreting 
serotonin, tachykinins,
 — PTHrPoma — secreting parathyroid hormone-
related peptide.
F-PNET may occur in the pancreas and in other 
locations. The clinical symptoms associated with the 
presence of such tumours are due to the hormones 
secreted by those neoplasms. For very rare tumours, 
the interpretation of the symptoms is often ambigu-
ous [9, 10].
It should be noted that the existence of somatosta-
tin tumour syndrome as a clinically separate disease 
entity has been questioned. In a study of  46 patients 
diagnosed with somatostatinoma, no one, nor any of 
821 other PNET patients, presented with a complete set 
of the proposed signs of the clinical somatostatinoma 
tumour syndrome [11].
Very rare syndromes associated with F-PNET (1–5 
cases) include:
 — reninoma — secreting renin,
 — LHoma — secreting luteinising hormone,
 — tumour secreting erythropoietin,
 — tumour secreting insulin-like growth factor-2 
(IGF-2),
 — cholecystokininoma — secreting cholecystokinin 
(CCK),
 — PNET secreting GLP-1 — glucagon-like peptide-1 
(GLP-1).
Most PNETs are sporadic (non-hereditary) tumours, 
although various rates of F-PNETs occur as components 
of hereditary syndromes. Multiple endocrine neopla-
sia type 1 (MEN-1) is the most significant hereditary 
disease, responsible for 20–30% of gastrin-secreting 
tumours and < 5% of insulin-secreting tumours or 
RFT [12–15]. Rare causes of hereditary PNET include 
von Hippel-Lindau (VHL) disease, von Recklinghausen 
disease (neurofibromatosis type 1, NF-1), and tuberous 
sclerosis [12, 13]. Of all VHL patients, 10–17% develop 
NF-PNET, < 10% of patients with NF-1 almost always 
develop duodenal somatostatin-secreting tumours, 
and F-PNET or NF-PNET occur in 1% of patients with 
tuberous sclerosis [12].
1.2. Clinical characteristics of PNEN
1.2.1. Functional pancreatic neuroendocrine  
neoplasms (F-PNEN)
Insulinoma — this insulin-secreting pancreatic tumour 
is the most common functioning neuroendocrine tu-
mour of the pancreas. In approximately 1% of patients 
an extra-pancreatic location is possible (duodenum, 
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stomach, bile ducts, or lungs) [6, 16]. Its case incidence 
rate is estimated at 1–3/1,000,000/year. The highest 
incidence is observed in the fifth decade of life (be-
tween the ages of 40 and 45 years), and slightly more 
often in females (60%). Less than 10% of all tumours 
are malignant [9]. Insulinoma is usually single, and 
only 10% of patients have multiple tumours (often 
of multiple endocrine neoplasia type 1 [MEN1]). In 
approximately 4-5% they are associated with MEN1 
syndrome [6, 9, 16–18]. Clinical symptoms result from 
hypoglycaemia rather than from the presence of a tu-
mour (which is usually no more than 2 cm in diameter). 
Clinical symptoms of neuroglycopaenia are: pains 
and vertigo, blurred vision, double vision, abnormal 
behaviour, confusion, concentration disorders, retro-
grade amnesia, drowsiness, hallucinations, delusions, 
and convulsions. In approximately 12% of patients, 
loss of consciousness occurs with grand mal seizures 
[6, 19]. Severe hypoglycaemia may result in death. 
Decreased blood glucose levels also cause increased 
secretion of catecholamines, and therefore: paleness, 
increased perspiration, hand tremors, nausea, palpi-
tations, hunger (often increased body weight), and 
weakness. Although hypoglycaemic episodes usually 
occur several hours after a meal, often in the morning, 
irregularly, and of different durations, in some patients 
(up to 18%) hypoglycaemia may only occur soon after 
a meal [20–22]. They may be triggered by physical ef-
fort, consumption of ethyl alcohol, or low-calorie diet 
[6, 9, 10, 17, 23, 24].
Prognosis: in benign tumours — very good; in over 
95% of such patients a surgical procedure results in 
complete recovery. In patients with distant metastases, 
mean survival time is less than two years. Tumour dia-
meter > 2 cm, Ki-67 > 2%, and various molecular and 
chromosomal disorders, e.g. loss of 3p or 6q, are factors 
associated with decreased survival [6, 10, 17, 18, 23, 24].
Gastrinoma — these gastrin-secreting tumours are 
discussed in the section: "Gastroduodenal neuroendo-
crine neoplasms including gastrinoma — management 
guidelines (recommended by the Polish Network of 
Neuroendocrine Tumours)" (see p. 138–153).
Other functional pancreatic NENs, classified as rare 
and very rare, are presented in Table I and II.
Table I. Rare Functional Tumours, RFT [9, 25, 26]
Rare Functional 
Tumours, RFT
Secreted 
substance
Frequency Malignant
tumours
MEN-1 Site Symptoms
Glucagonoma Glucagon 0.01–0.1/
/1 million/year
50–80% 1–20% Pancreas 100% Necrolytic erythema (67–90%), 
glucose intolerance (38–87%),  
body weight loss (66–96%),  
stomatitis, diarrhoea and 
hypoaminoacidemia
VIPoma
[Verner-Morrison 
syndrome, pancreatic 
cholera, WDHA 
syndrome]
Vasoactive 
intestinal peptide
0.05–0.2/
/1 million/year
40–70% 6% Body of the pancreas 
(90%, adults), 
sympathetic system, 
liver, adrenal glands
Diarrhoea (90–100%), hypokalemia 
(80–100%), dehydration (83%), 
acidosis, rarely skin reddening, 
hyperglycaemia, glucose intolerance 
and functional gallbladder disorders; 
WDHA syndrome – Watery 
Diarrhoea, Hypokalemia,  
Achlorhydria
Somatostatinoma Somatostatin Very rare > 70% 45% Pancreas (55%), 
duodenum/small 
intestine (44%)
Cholelithiasis (65–90%), diabetes 
(63–90%), diarrhoea (35–90%), body 
weight loss
GHRHoma Growth-hormone-
releasing hormone
Unknown > 60% 16% Pancreas (30%), 
lungs (54%), small 
intestine (7%), others 
(13%)
Clinical signs of acromegaly (100%)
ACTHoma Corticotrophin Rare > 95% Rare Pancreas 
(4–16%), others 
– extrapancreatic 
location
Cushing’s syndrome (100%)
FP-NET causing 
carcinoid syndrome
Serotonin, 
tachykinins
Very rare 60–88% Rare Pancreas < 1% Carcinoid syndrome
PTHrPoma Parathyroid 
hormone-related 
peptide
Very rare 84% Rare Pancreas Hypercalcaemic syndrome or, in 
the case of hepatic metastases, 
abdominal pain
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Prognosis: in RFT depends on the size of the tu-
mour and the presence of distant metastases. Five-year 
survival in advanced stages of the disease is estimated 
at 29–45%. Unfavourable prognosis is determined by: 
Ki-67 > 2%, presence of distant metastases, chromosomal 
disorders, and presence of cytokeratin-19 [9, 10, 25–27].
1.2.2. Non-functioning pancreatic neuroendocrine 
neoplasms (NF-PNENs)
Non-functioning pancreatic neuroendocrine neo-
plasms (NF-PNENs) do not cause the characteristic 
symptoms of hormonal hypersecretion. In some 
tumours, immunohistochemical methods have re-
vealed the presence of various hormonal substances 
produced by these neoplasms, but these are either not 
secreted into the blood circulation or they are secreted 
in quantities that do not result in clinical symptoms. 
Most NF-PNENs are well-differentiated tumours. 
Their incidence rate is 1.8/1,000,000/year in females 
and 2.6/1,000,000/year in males. The frequency of their 
detection increases with age, with peak incidence 
in the 6th and 7th decades of life. In 3–53% of cases 
(mean 19%) they are associated with MEN1 syndrome 
(the frequency is age-related, being higher in elderly 
patients), and in 13–17% of cases with von Hippel-
Lindau (VHL) syndrome [6, 28–32].
Symptoms: NF-PNENs are usually diagnosed late, 
when they are of a large size, cause pressure on the 
adjacent organs or invade them, or produce distant me-
tastases [6, 8, 28]. The most common symptoms include: 
abdominal pain (35–78%), weight loss (20–35%), loss of 
appetite, and vomiting (45%). Less common are internal 
haemorrhages (4–20%), jaundice (17–50%), or palpable 
tumours in the abdominal cavity (7–40%) [6, 8, 33–35]. 
Some studies demonstrate that hepatic metastases are 
observed in 32% of patients newly diagnosed with 
NF-PNET [38]. This value is significantly lower than that 
observed in previous studies (46–73%) [6, 30, 37–39].
Prognosis: The mean survival time of patients with 
NF-PNETs in currently available studies is 38 months, 
with a five-year survival of 43% [8, 30]. The mean sur-
vival of patients with distant metastases was approxi-
mately 23 months, compared to a 70- and 124-month 
survival rate in the case of a localised disease [6, 8, 30, 
40]. The histological grading of the tumour is also an 
important factor affecting the survival time [8, 41]. 
Other unfavourable prognostic factors include: age 
> 40 years, dynamic development of hepatic metastases 
(25% increase in their volume over 6–12 months), and 
occurrence of osseous metastases [6, 8].
Recently, new data has been presented in the lit-
erature:
 — it has been demonstrated that calcifications in 
a pre-operative CT examination in patients with 
PNETs (observed in 16% of cases) correlate with 
the degree of malignancy and the presence of 
lymph node metastases in well-differentiated 
PNETs [42],
 — the extent of hepatic metastases, involving one 
or two lobes, or the presence of other metastases 
in the abdomen are important predictive factors 
for survival, regardless of the tumour malignancy 
(Ki-67) [43],
 — it has been observed that in most patients with 
advanced PNENs the neoplasm progresses. Its best 
prognostic factor is the Ki-67 index value [44],
 — the involvement of lymph nodes and the number 
of involved lymph nodes in patients with PNENs 
is of significant prognostic value,
 — an absence of symptoms is associated with signifi-
cantly better prognosis, regardless of the stage of 
the neoplasm, in particular in NF-PNETs.
Currently, prognosis in patients with PNETs in the 
course of MEN-1 is uncertain due to the high and con-
stantly improving effectiveness of F-PNET treatment 
in the course of MEN-1 [12–14].
Table II. Very rare syndromes associated with functional pancreatic tumours (F-PNETs) [12–15]
Very rare syndromes 
associated with F-PNET
Secreted 
substance
Malignant 
tumours
Site Symptoms
Reninoma Renin Pancreas Arterial hypertension,
LHoma Luteinising 
hormone
Pancreas Lack of ovulation, virilisation in women, reduced libido in men
Tumour secreting erythropoietin Erythropoietin 100% Pancreas Polycythemia
Tumour secreting insulin-like 
growth factor-2
IGF-2 Pancreas Hypoglycaemia
Cholecystokininoma Cholecystokinin 
(CCK)
Pancreas Diarrhoea, ulcer disease, weight loss, cholelithiasis
Tumour secreting glucagon-like 
peptide-1
GLP-1
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2. Diagnostics
2.1. Biochemical diagnostics
The biochemical diagnostics of the hormones and mark-
ers secreted by PNENs may be helpful in three aspects: 
initial diagnosis of the disease, assessment of treatment 
efficacy, and prognosis.
2.1.1. Functional pancreatic neuroendocrine  
neoplasms (F-PNENs)
The biochemical diagnostics of all F-PNENs requires 
evidence of increased serum concentrations of specific 
hormonal markers (e.g. gastrin in the Zollinger-Ellison 
syndrome or insulin in insulinoma) in combination with 
clinical symptoms and laboratory changes indicating 
hypersecretion of a given, such as excessive secretion 
of gastric juice in ZES, hypoglycaemia in insulinoma, 
etc. [6, 11]. In a great number of sporadic PNENs, the 
type of cells may change and tumours may produce 
various additional peptides (apart from those specific 
for the tumour). This is related to the worsening of 
the prognosis, especially when the tumour ectopically 
secretes ACTH [6, 45, 46].
Most insulinomas are benign tumours with proper 
serum CgA levels, which may, however, increase if 
the tumour is malignant or metastatic. According to 
some reports, CgA concentration is not always useful 
in the diagnostics of patients with insulin-secreting 
tumours (specificity of only 73%), contrary to other 
PNETs [47].
A positive Whipple’s triad is helpful in diagnosing 
insulinoma:
1. Autonomous clinical symptoms suggesting hy-
poglycaemia.
2. Spontaneous hypoglycaemia.
3. Symptoms resolve quickly following the intake o f 
simple carbohydrates.
There is evidence of reduced glycaemia during the 
symptoms (< 40 mg/dL; 2.2 mmol/L) with uninhibited 
insulin secretion.
Previous criteria for diagnosing insulinoma:
The diagnosis of insulinoma is based on the follow-
ing criteria:
 — documented glycaemia ≤ 2.2 mmol/L (≤ 40 mg/dL) and 
concomitant inadequate concentration of insulin 
≥ 6 mU/L (≥ 36 pmol/L);
 — C-peptide concentration ≥ 200 pmol/L;
 — proinsulin concentration ≥ 5 pmol/L.
Interpretation of the above criteria should include 
drug-induced hypoglycaemia by verifying the serum 
and/or urinary levels of sulphonylurea and its metabo-
lites [6, 11].
It should be emphasised that diagnostic criteria of 
insulin-secreting tumours are constantly changing, and 
differ with regard to individual diagnostic propositions 
or consensus reviews. For instance, the US Endocrine 
Society proposed the following diagnostic criteria: 1. 
endogenous hyperinsulinism resulting in symptoms, 
signs, or both, with glucose plasma concentration 
of < 55 mg/dL (3 mmol/L), insulin concentration of 
> 3.0 µU/mL (18 pmol/L), C peptide concentration of 
> 0.6 ng/mL (0.2 nmol/L), and proinsulin concentra-
tion of > 5.0 pmol/L. In unclear cases the presence 
of plasma ß-hydroxybutyrate in the concentration of 
< 2.7 mmol/L and plasma glycaemia increased to 
> 25 mg/dL (1.4 mmol/L) following intravenous ad-
ministration of glucagon indicates insulin-dependent 
(or IGF-dependent) hypoglycaemia. Use of 3 instead 
of 5 µU/mL as the limit value of insulin is supported 
by a study demonstrating that using a limit value of 
> 5 µU/mL would result in missing 9% of the patients 
with insulin-secreting tumours [48]. Another study 
revealed that in certain patients with insulin-secreting 
tumours (23%) the plasma b-hydroxybutyrate concen-
tration may be > 2.7 mmol/L, especially if the patients 
underwent partial pancreatectomy, and were examined 
for any recurrence [48].
Some studies confirm that in patients with MEN-1, 
insulin-secreting tumours are found more frequently 
than gastrin-secreting tumours and in 25% of patients 
insulinoma occurs before the age of 20 years [12, 49, 50]. 
Therefore, if an insulin-secreting tumour is found in 
a patient under 20 years old, or if multiple insulin-
secreting tumours are found regardless of age, MEN-1 
should be suspected, and suitable genetic tests per-
formed [26, 52, 53].
When diagnosing insulinoma, the 72-hour fasting 
test is still the gold standard, although some stud-
ies report that a 48-hour test may be sufficient. The 
fasting test is performed under inpatient conditions, 
with serial measurements of the blood glucose con-
centration. Patients with insulinoma usually develop 
hypoglycaemia within 24 hours. In 5% of patients, hy-
poglycaemia may occur after meals [6, 54]. If symptoms 
of hypoglycaemia occur and the blood glucose level is 
≤ 2.2 mmol/L (≤ 40 mg/dL), blood should be collected 
for C-peptide, proinsulin, and insulin assays. The lack 
of adequate suppression of insulin in hypoglycaemia 
confirms the presence of an independently secreting 
insulinoma-type tumour [6, 11].
In one of the studies, the most sensitive criterion for 
diagnosing insulinoma was the coexistence of elevated 
proinsulin levels and fasting glycaemia of ≤ 2.5 mmol/L 
(≤ 45 mg/dL) [6,11].
Gastrinoma
The biochemical diagnostics of gastrinoma is dis-
cussed in the section on gastroduodenal NENs (see 
p. 138–153).
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2.1.2. Rare functional pancreatic neuroendocrine 
neoplasms (RF-PNEN)
The biochemical diagnostics of RF-PNEN includes 
confirmation of increased serum concentrations of spe-
cific biochemical markers, e.g. glucagon in suspected 
glucagonoma (positive result > 1000 pg/mL), vasoactive 
intestinal peptide (positive result > 170 pg/mL), and 
somatostatin (in the case of pancreatic tumour location, 
it is over 50 times higher than the reference values) [6].
Chromogranin A (CgA), which is a general marker, 
may only be used to confirm the presence of a neuroen-
docrine tumour and monitor the course of the disease, 
but it cannot constitute the basis for the diagnosis of 
a functional PNEN syndrome.
All biochemical tests should be performed during 
the first visit. Suspected Cushing’s syndrome due to 
PNEN should be confirmed in 24-hour urine collec-
tion or midnight serum cortisol measurements, or by 
determination of cortisol concentration in the saliva. 
If necessary, determination of cortisol inhibition with 
the use of a suitable dexamethasone suppression test 
should be performed.
The assessment of markers specific for NENs is use-
ful in the diagnosis and monitoring of various tumours. 
See Table III [6, 55]. Indications for their determination 
depend on the clinical status of the patient with PNEN.
Concentrations of certain peptides increase signifi-
cantly after meals, and may remain increased for as long 
as six hours following a meal. The blood for testing needs 
to be collected only in the morning, and under fasting 
conditions [6, 11]. In the case of CgA this is not required, 
but if blood samples are not collected under fasting 
conditions, this should always be recorded to ensure 
the proper interpretation of the results by the laboratory. 
One should note that concentrations of all PNEN blood 
markers, with the exception of insulin, are increased in 
patients with impaired renal function, so interpretation 
of the results in this group of patients may be difficult. 
Among the numerous markers assessed in the blood, 
CgA is a prognostic factor for most PNENs [6, 56, 57].
2.1.3. Non-functional pancreatic neuroendocrine 
neoplasms (NF-PNEN)
The biochemical in PNEN tests CgA is recommended, 
which is a marker for most NENs. The level of chro-
mogranin B (CgB) may be elevated if the level of CgA 
is within the reference range [6, 11, 58].
NF-PNENs can also secrete pancreatic polypep-
tide (PP). However, the percentage of patients with 
increased PP concentration is significantly lower than 
that of patients with increased CgA concentration [11]. 
The need for standardisation of CgA assays should be 
emphasised [6, 59, 60].
In the biochemical diagnostics of NF-PNENs the fol-
lowing markers are also used: neuron-specific enolase 
(NSE), whose sensitivity in NENs of G1 and G2 is 19% 
and 54%, respectively, and the β subunit of human cho-
rionic gonadotropin (βhCG). Neuron specific enolase is 
mainly determined in NEC, if the CgA concentration 
is normal [6].
2.1.4. Pancreatic neuroendocrine carcinomas
Concentration of CgA and other hormonal markers 
in this group of pancreatic NENs usually give nega-
tive results. NSE may be used as a marker for these 
neoplasms [6]. Its sensitivity is approximately 62–63%, 
and it also forms an independent prognostic factor for 
NEC [6, 61, 62].
Minimal consensus statement on biochemical tests:
Determination of plasma CgA level should be the basic 
biochemical test in patients with suspected PNENs. In 
non-functional PNENs, pancreatic polypeptide (PP) can be 
used (for early detection of PNENs in MEN-1 and PNECs, 
especially those with low CgA level).
Determination of specific markers (gastrin, insulin, 
serotonin, VIP, glucagon, etc.) should be performed if the 
patient presents symptoms suggestive of a hormonal clinical 
syndrome (*evidence level 3).
Specific dynamic tests are performed in individual cases.
Diagnostic examinations for MEN-1 are obligatory.
2.2. Pathomorphological diagnostics
2.2.1. Pathogenesis and prognosis
The term “pancreatic neuroendocrine neoplasms” refers 
to tumours arising from a pluripotent stem cell of the 
Table III. Specific markers for various PNENs (modified 
according to [6, 55])
Tumour type PNEN markers
PNEN CgA
NF-PNEN PP, NSE, hCG
Insulinoma CgA, insulin, glucose
C-peptide or proinsulin
Gastrinoma Gastrin
Glucagonoma Glucagon, enteroglucagon
VIPoma VIP
Somatostatinoma SST
PPoma PP
MEN1 CgA, gastrin, calcium, PTH, insulin, 
glucagon, PP
CgA — chromogranin A; hCG — human chorionic gonadotropin; NSE — neuron 
specific enolase; PP — pancreatic polypeptide; PTH — parathyroid hormone; 
SST — somatostatin; VIPoma — tumour secreting vasoactive intestinal peptide
*evidence level according to OCEMB [252]
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pancreatic ducts with neuroendocrine differentiation. 
The term “islet cell tumour”, frequently used in the past, 
is incorrect due to NEN histogenesis, because these neo-
plasms do not arise from pancreatic islets [6]. All pan-
creatic neuroendocrine neoplasms (PNEN) of at least 
0.5 cm in diameter are malignant neoplasms, regardless 
of their histological type. Only a microadenoma of less 
than 0.5 cm diameter can be a benign form.
2.2.2. Diagnostic algorithm
Pathomorphological diagnostics of NENs are based on 
the standardised World Health Organisation (WHO) 
classification [63]. The pathomorphological diagnosis 
is confirmed by immunohistochemical methods, to 
assess the expression of neuroendocrine markers: chro-
mogranin A (CgA) and synaptophysin, and the Ki-67/ 
/MIB1 proliferation index [6]. Immunohistochemical 
examination of the hormonal substances produced by 
pancreatic cells is insufficient for the diagnosis of func-
tional or non-functional tumours [64]. Pancreatic cells 
may demonstrate immunohistochemical expression 
of the analysed products even in minimal quantities, 
without any clinical significance.
The histopathological diagnostics of PNENs requires 
an assessment of:
 — histological type according to the WHO 2017 clas-
sification [63], comprising well-differentiated NETs, 
and poorly differentiated neuroendocrine tumours, 
referred to as neuroendocrine carcinomas (NECs),
 — histological grade (G, grading), which is important 
from the prognostic and predictive points of view, 
especially in NENs. It is recommended that it is as-
sessed in each case, both in tumours removed sur-
gically and in biopsies, if the quantity of neoplastic 
tissue is sufficient. The assessment of the G feature is 
based on two criteria: the number of mitotic figures 
in 10 high-power fields under a light microscope, 
with magnification of 40x, and proliferation index 
Ki-67. The principles for the assessment of these 
two parameters according to ENETS/WHO are 
presented in Table IV in "Diagnostic and therapeutic 
guidelines for gastro-entero-pancreatic neuroendo-
crine neoplasms" (p. 79–110).
Well-differentiated tumours demonstrate a prolifera-
tion index of below 20%, and below 20 mitotic figures in 
10 HPF. According to both criteria, the above-mentioned 
tumours are divided into two groups: NETs of G1 and 
NETs of G2, as presented in Table IV in Diagnostic and 
therapeutic guidelines for gastro-entero-pancreatic neuroen-
docrine neoplasms (p. 79–110). NETs demonstrate intense 
and extensive immunohistochemical expression of syn-
aptophysin and chromogranin A (CgA). Feature G3 is 
characteristic of neoplasms with over 20 mitotic figures 
in 10 HPF, and a proliferation index of over 20%. These 
tumours may present a low immunohistochemical ex-
pression of synaptophysin and CgA. It should be noted 
that rarely, in certain well-differentiated neuroendocrine 
tumours (NETs), a high proliferative activity of over 20% 
and over 20 mitotic figures in 10 HPF may occur. These 
neoplasms, on the basis of feature G, were previously 
classified as neuroendocrine carcinomas (NECs). How-
ever, due to different prognosis and treatment methods 
for this group of patients, they have been distinguished 
from NECs under the term of well-differentiated G3 
neuroendocrine tumours (G3 NETs) [63, 65–68]. This 
classification in presented in Table V in "Diagnostic and 
therapeutic guidelines for gastro-entero-pancreatic 
neuroendocrine neoplasms" (p. 79–110).
 — pTNM stage of pathological advancement accord-
ing to ENETS [69] and TNM AJCC Eighth Edition 
of 2017 [65] and UICC 8 2017 [70], which are identi-
cal for PNENs. The most reliable assessment of the 
stage can be made on the basis of an examination of 
the tumour along with surgically removed lymph 
nodes, and data regarding the presence of distant 
metastases.
Table IV. ENETS and TNM AJCC/UICC classification 8. Edition 
2017 [65, 69, 70]
Feature T 
according 
to TNM
TNM ENETS TNM AJCC/UICC, 2017
TX Tumour has not been 
assessed
Tumour has not been 
assessed
T1 Tumour limited to the 
pancreas, < 2 cm in 
diameter
Tumour limited to the 
pancreas, < 2 cm in 
diameter
T2 Tumour limited to the 
pancreas, 2–4 cm in 
diameter
Tumour limited to the 
pancreas, 2–4 cm in 
diameter
T3 Tumour limited to the 
pancreas, > 4 cm in 
diameter or invading the 
duodenum / bile tract
Tumour limited to the 
pancreas, > 4 cm in 
diameter or invading the 
duodenum or bile tract
T4 Invasion of adjacent 
organs or the walls of 
large vessels
Tumour invading adjacent 
organs (stomach, spleen, 
colon, adrenal gland) or 
walls of the main vessels 
(coeliac trunk, superior 
mesenteric artery)
Table V. Clinical staging of PNENs according to TNM AJCC 8, 
UICC 8. Edition 2017 [65]
Clinical stage Comments
Stage I T1 N0 M0
Stage II T2-3 N0 M0
Stage III T4 N0 M0, any T N1 M0
Stage IV Any T, any N, M1
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Feature N, describing the lymph node status, has two 
degrees: N0 if no lymph node metastases were found, 
and N1 if metastases to lymph nodes were observed. 
The number of lymph nodes examined in the surgical 
material depends on the type of surgery, but 12 lymph 
nodes are considered optimal. The most recent, Edition 
8 of the TNM UICC classification, additionally distin-
guishes between N1: metastases to 1–3 lymph nodes, 
and N2: metastases to four or more lymph nodes [70].
Feature M, describing distant metastases, is defined 
as follows: M0 if no distant metastases were found; M1 
if distant metastases were found, with M1a meaning 
metastases limited to the liver, M1b meaning metastases 
to at least one extrahepatic organ (lung, ovary, extra-
regional lymph nodes, peritoneum, bones), and M1c 
meaning metastases defined by M1a and M1b.
The clinical staging of PNENs according to TNM 
UICC 8
 — since 2017 [70], it is slightly different.
 — Each diagnosis of NEN must be confirmed by im-
munohistochemical examinations with the use 
of antibodies against chromogranin A (CgA) and 
synaptophysin, and by the Ki-67/MIB1 proliferative 
activity assessment;
 — In certain cases, products secreted by NENs, such as 
gastrin, insulin, or glucagon, may be assessed. These 
markers are more useful for detecting the metastases 
of functional tumours, especially if the original site 
is unknown [65].
 — The clinical staging of NENs is presented in Table III.
2.2.3. Prognostic indicators in the histopathological 
report
In the histopathological examination it should be 
noted that nodules smaller than 5 mm are referred to 
as microadenoma, and are not considered in the histo-
pathological report. Multiple foci are characteristic for 
PNENs, especially in MEN1, in over 30% of gastrinoma 
cases and 13% of insulinoma cases. Therefore, a very 
careful microscopic assessment of the surgical material, 
involving cross-sections of the pancreatic parenchyma 
at 3- to 5-mm intervals, is necessary. In each case, the 
assessment of resectability is an important prognostic 
parameter. In order to perform this, it is necessary to 
evaluate macroscopically and microscopically the surgi-
cal margins: of the common bile duct, transpancreatic 
with the pancreatic duct, retroperitoneal, and radial, 
created by the posterior wall of the surgical material. 
Evaluation of the margins of the duodenum, stomach, 
and other soft tissues forming the surgical margins is 
recommended, as well as assessment of the vascular 
and neural invasions, because they are associated with 
lymph node metastases and shorter life expectancy, ac-
cording to some clinical studies. Coagulative necrosis, 
either local or geographic, is another prognostic factor, 
because it correlates with a high grade of histological 
malignancy of the tumour.
The morphological picture of the tumour, compris-
ing tumour tissue architecture and characteristics of 
its cells, is also reflected in the tumour differentiation 
stage [6, 71, 72]. Under a light microscope, a pancre-
atic neuroendocrine neoplasm usually corresponds to 
a well-differentiated tumour, or a small-cell or large-
cell neuroendocrine carcinoma. Organoid structures 
in the form of solid nests, trabecular or labyrinthine 
systems, or structures resembling glands and rosettes, 
are characteristic. They are accompanied by a varying 
quantity of tumour stroma and numerous blood vessels 
surrounding the tumour nests. It is worth emphasising 
that amyloid deposits are typical for a functional tumour 
such as insulinoma, whereas glandular-like structures 
and psammomatous bodies are characteristic of soma-
tostatinoma. Features of neuroendocrine tumour cells 
are well known to differ from other neoplasms. They are 
small or medium-sized, with acidophilic or amphophilic 
and granular cytoplasm. The nuclei are round or oval, 
usually situated centrally in the cell. A typical feature 
of NEN, which helps to distinguish it from adenocar-
cinoma, is fine-grained chromatin, referred to as “salt 
and pepper”. Apart from the above typical features 
of neuroendocrine tumours, their cells may present 
a different picture, creating oncocytic, clear cell, fat-rich, 
and rhabdoid-type variants. Pancreatic neuroendocrine 
neoplasms may then resemble melanoma, clear cell renal 
cell carcinoma, or adrenal cortical carcinomas. Diagnos-
tic errors are caused by incorrect differentiation between 
PNEN and pancreatic ductal adenocarcinoma or acino-
cellular carcinoma, solid pseudopapillary neoplasms, 
or clear cell carcinoma metastases from other organs.
To sum up, pathomorphological diagnostics of 
pancreatic NENs requires experience on the part of the 
pathomorphologist, the co-operation of an interdisci-
plinary team of specialists, and access to an immuno-
histochemical laboratory [6].
Minimal consensus statement on pathomorphological 
examinations:
A minimal histopathological report for PNEN should 
include:
 — histological type of the neoplasm, considering the divi-
sion into well-differentiated neuroendocrine neoplasms 
(NENs), neuroendocrine carcinomas (NECs), and 
mixed neuroendocrine non-neuroendocrine neoplasms 
(MINEN),
 — histological G grading referring to well-differentiated 
neoplasms (G1 NET, G2 NET, or G3 NET) and NEC, 
including division between large-cell and small-cell neu-
roendocrine cancer (the diagnostic criteria are presented 
in Table IV and V in section 2.2),
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 — pTNM staging according to ENET and TNM AJCC 
classifications (it is important to provide affiliation of the 
classification in each case),
 — assessment of surgical margins.
The histopathological diagnosis of NEN must be confirmed 
by immunohistochemical tests assessing the expression of the 
neuroendocrine markers: synaptophysin and chromogranin A 
(CgA), as well as Ki-67 proliferative activity using the MIB1 
antigen [6, 73] (*evidence level 3).
2.3. Location diagnostics
2.3.1. Endoscopic diagnostics
Classical gastrointestinal endoscopy is practically of no 
relevance for the diagnostics of PNENs [6].
In the case of functional lesions secreting gastrin, the 
changes in the upper gastrointestinal tracts, including 
treatment-resistant, severe reflux oesophagitis, often 
multiple digestive ulcers of the stomach and duode-
num, and hyperplasia of the gastric mucosa may justify 
further diagnostics (see p. 138–153).
In rare cases, the lesions, both functional and non-
functional, may cause compression of the main pan-
creatic duct or bile ducts, and once the non-invasive 
diagnostic methods have been exhausted, endoscopic 
retrograde pancreatocholangiography plays an impor-
tant role, especially in therapy [74, 75].
2.3.2. Ultrasonographic examinations
2.3.2.1. Transabdominal ultrasonography
The sensitivity of conventional ultrasonography (USG), 
mostly performed as the first-line examination in detect-
ing primary tumours and in assessing the staging of the 
disease, is low for small tumours. On average, ultrasonog-
raphy detects approximately 30% of primary insulinomas 
and gastrinomas. The sensitivity of this method increases 
for detecting hepatic metastases, where it amounts to 
50–80%. For larger tumours, mostly non-secreting pan-
creatic tumours and late-diagnosed glucagonoma, the 
sensitivity of transabdominal USG is higher [6, 76–78].
Currently, third-generation contrast agents are 
being introduced to the diagnostic process. They are 
composed of gas microbubbles in a phospholipid shell, 
characterised by a long half-life in the bloodstream and 
enhanced, perfusion-dependent greyscale. Studies are 
being conducted on the use of contrast enhanced ultra-
sound (CEUS) for the differential diagnostics of pan-
creatic tumours, including PNENs [79]. CEUS detects 
tumours smaller than 2 cm in diameter with sensitivity 
comparable to EUS (95%). With respect to PNENs, the 
sensitivity of the method is up to 94%, the specificity 
reaches 96%, the positive predictive value is 75%, and 
the negative predictive value is up to 99%. The image 
of neuroendocrine neoplasms has a characteristic echo 
pattern after intravenous administration of the contrast 
agent: in the arterial phase, echogenicity increases in-
tensively and quickly decreases as the contrast agent 
washes out in the venous phase [11].
2.3.2.2 Endoscopic ultrasonography
Endoscopic ultrasonography (EUS) enables precise im-
aging of the pancreas, and it is the most sensitive of the 
methods currently used in the diagnosis of pancreatic 
focal lesions (it detects lesions of 1–2 mm in diameter); 
a negative result of EUS practically exclude the presence 
of a pancreatic tumour [6, 80]. A biopsy is recommended 
to confirm the neoplastic character of the lesion [81, 82].
EUS enables:
 — locating of hormonally functional neoplasms (di-
agnosed on the basis of clinical and/or biochemical 
symptoms);
 — obtaining material for histopathological/cytological 
examination;
 — tattooing of small focal lesions before the planned 
surgical treatment;
 — diagnostic imaging of non-functional PNENs;
 — screening tests in patients with MEN1.
In the case of small insulin-secreting tumours, EUS 
sensitivity is up to 94–100% [83–86]. Diagnostic sen-
sitivity of the examination in pancreatic gastrinoma 
tumours is nearly 100%, but it decreases in the case 
of multifocal or extra-pancreatic lesions; in the case of 
gastrin tumours located in the duodenum and outside 
the pancreatic parenchyma, the sensitivity of the test 
is estimated to be approximately 50% [6, 84]. Typically, 
functional tumours in an echoendoscopic image are 
single, homogeneous, regular, solid lesions with an 
echo signal reduced comparing to the pancreatic paren-
chyma (86% of lesions). Normoechoic or hyperechoic 
nodules are rare. Lesions may be of the form of a cyst 
in about 10–20% of patients [6].
EUS is also important in differential diagnosis of 
pancreatic tumours of indetermined character, and 
in the pre-operative assessment of staging. Specific 
ultrasonographic features allow distinction between 
pancreatic carcinomas and neoplasms of neuroendo-
crinal origin, as well as between functional and non-
functional tumours [6, 87]. The usefulness of EUS in 
the assessment of staging has also been confirmed, 
particularly for the evaluation of vascular invasion and 
tumour staging [6, 88, 89].
EUS is also used to perform fine-needle and large-
needle biopsies through the gastric/duodenal wall. It 
is believed that this route of access, compared to per-
cutaneous biopsy, reduces the risk of spreading of the 
*evidence level according to OCEMB [252]
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neoplastic cells [6]. The average sensitivity and speci-
ficity of EUS combined with biopsy in the diagnostics 
of pancreatic NENs is 84% and 92.5%, respectively. In 
a study published this year [90] the authors reported 
90% effectiveness of this method in the diagnosis of 
PNETs, and 43% accuracy in the assessment of the level 
of differentiation.
At the pre-operative stage it is possible to inject blue 
dye into the tumour EUS tissue, which enables faster 
intraoperative localization of the lesion. This method is 
of particular use in laparoscopic procedures, in which it 
is impossible to detect the pancreatic lesions by palpa-
tion. Moreover, precise localization of the lesion helps to 
keep a proper resection margin, and preservation of the 
healthy pancreatic tissue. However, it should be stressed 
that tattooing may cause acute pancreatitis [6, 91, 92].
MEN-1 syndrome is a particular indication for EUS. 
The incidence of pancreatic lesions in this group of pa-
tients is estimated at 40–80%. Functional tumours can 
be detected early, due to typical clinical and biochemical 
symptoms, but non-functional tumours (approx. 50% 
of lesions) in most patients are diagnosed late, which 
determines their poor prognosis. EUS is recommended 
as the most sensitive and cost effective method of 
monitoring these patients because early detection of 
a pancreatic lesion enables radical treatment [6].
2.3.2.3. Intraductal ultrasonography
Intraductal ultrasonography (IDUS) may surpass EUS 
in the detection of PNENs. In this method, a probe 2 
cm in diameter is introduced into the duct of Wirsung 
through the duodenoscope channel [6].
2.3.2.4. Intraoperative ultrasonography
The sensitivity of intraoperative ultrasound (IOUS) in 
the detection of small PNENs is similar to that of EUS. 
The sensitivity of this examination, combined with 
intraoperative palpation assessment, is up to 97%. In 
the case of gastrinoma, the sensitivity of the test within 
the pancreas is close to 100%, but decreases to 58% with 
an extra-pancreatic location. Intraoperative IOUS also 
allows detection of multifocal tumours and metastases 
in the liver,
and the assessment of the distance between the 
tumour, especially a small one, and the pancreatic duct, 
in order to properly evaluate the patient’s eligibility for 
tumour resection or enucleation [93]. An IOUS examina-
tion is also performed during laparoscopy [6].
2.3.3. Computed tomography (CT) and magnetic 
resonance imaging (MRI)
Presently, according to current guidelines, a spiral 
multidetector CT (multidetector computed tomogra-
phy, MDCT) and MR imaging are used for the diagno-
sis of parenchymal abdominal organs, including the 
pancreas. These methods are especially important in 
assessing the stage of neoplastic disease, and in moni-
toring the response to treatment [6, 94]. They are also 
useful for assessing the anatomical location and the 
resectability of the primary lesion [6].
2.3.3.1. Computed tomography (CT)
Computed tomography enables a targeted biopsy from 
the lesion to be performed. The sensitivity of each 
imaging method depends on the location and type of 
tumour [6, 85, 95].
Prior to administration of the contrast agent, 
functional PNENs are usually isodense, rarely hy-
podense in comparison to the remaining pancreatic 
parenchyma, and calcifications are clearly visible. Most 
tumours are well-vascularised (80% of insulinomas), 
so MDCT is intensively enhanced in the arterial 
phase. Metastases demonstrate a similar behaviour. 
Therefore, the MDCT should cover both the pancreas 
and liver in the arterial phase. In this phase of the test 
it is also possible to assess the tumour/coeliac artery 
relation. In the parenchymal phase only the pancreas 
is assessed tumour morphology and contrast wash 
out. The portal venous phase includes the pancreas, 
liver, and hepatic portal system [6, 96]. Delayed phase 
scan has been also proposed 150–180 seconds after 
the administration of the contrast agent, to further 
assess wash out of the contrast material from the tu-
mour [6, 97]. In typical neuroendocrine tumours, the 
contrast enhancement should decrease in the delayed 
phase relative to the arterial phase by at least 60 HU. 
Other types of enhancement in PNEN include uneven 
washout of the contrast agent (from over one half of 
from less than one half of the tumour mass) or slow 
increase of enhancement if the tumour is more visible 
in the equilibrium phase, over which the attenuation 
of the normal pancreatic parenchyma decreases. Such 
behaviour is characteristic of tumours with a high con-
nective tissue content. In parenchymal and delayed 
phases, neuroendocrine neoplasms are not always 
isodense and thus invisible in the CT scan. Some 
of these neoplasms maintain enhancement or show 
initial uptake of the contrast agent, in these phases. 
Slightly enhanced neoplasms are usually poorly dif-
ferentiated, so the level of enhancement correlates 
with the patient survival [6, 98–101].
Non-functional tumours present a lower contrast 
enhancement, and are heterogeneous due to necrotic 
areas. Calcifications in adenocarcinomas are very rare, 
whereas in functioning and non-functioning PNENs 
they are found in at least 25% of cases. In larger tumours 
the pancreatic duct is dilated, and parenchymal atrophy 
is observed. Infiltration of the adjacent structures and 
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distant metastases are the only features that distinguish 
malignant from benign lesions. Hepatic metastases are 
detected in the arterial phase  of the examination [6, 95].
Due to the shorter scanning time, the reduced num-
ber of movement artefacts, and thin (1–2 mm) tissue 
layers, MDCT enables multi-dimensional and spatial 
reconstructions that facilitate the imaging of structures 
smaller than 1 cm, and allow a complete assessment 
of the vascular invasion of the tumour [100, 101]. The 
sensitivity of contrast-enhanced MDCT using 1-mm 
layers in the diagnosis of insulinoma reaches 85–94%, 
whereas for various types of NENs the sensitivity of 
multidetector CT is 50–90% and the specificity is 96% 
[6, 102, 103, 8]. The role of CT scans in the assessment 
of PNEN includes the description of tumour mor-
phology, with precise localization and in case of any 
organ-transgressing infiltration, also determination of 
the adjacent fat tissue invasion, infiltration of the duo-
denum, common bile duct, stomach, spleen, intestinal 
loops, adrenal glands, as well as determination of arte-
rial and venous invasion, providing information about 
the invaded part and the length of the vessel. The de-
scription should also contain information concerning 
enlarged regional lymph nodes and the assessment of 
the liver for metastases. Assessment according to TNM 
classification should be possible on the basis of the CT 
description [6, 7]. The description should also contain 
the assessment of the tumour’s resectability, according 
to the NCCN criteria [6, 104].
2.3.3.2. Magnetic resonance (MRI)
In the diagnosis of PNEN, MRI conducted according 
to an optimum protocol is of sensitivity similar to that 
of CT, of 80–90%. MRI offers a higher tissue resolution 
combined with multi-dimensional imaging. Limitations 
of this method include: lover availability (in comparison 
with CT scanning), higher price, longer duration of the 
examination, and the necessity of patient co-operation. 
The method is recommended particulary for younger 
patients to save them ionising radiation exposure, and 
also in patients whose CT scan is inconclusive. Neu-
roendocrine tumours are hypointense on T1-weighted 
images, and hyperintense on T2-weighted images. In-
travenous administration of the contrast agent increases 
the sensitivity of the method [6, 96]. In a multi-phase 
examination following the intravenous administration 
of the contrast agent, the images are enhanced similar 
to the CT enhancement pattern above.
Following contrast administration, a 3D examina-
tion in a T1 sequence using a thin layer (1–2 mm) is 
recommended.
In addition, in MR spectroscopy, which uses 
chemical shift, it is possible to determine the chemi-
cal composition of the tissues. A relatively increased 
lipid content in NENs facilitates differentiation in 
ambiguous cases.
In recent years, a diffusion-weighted imaging (DWI) 
method has also been used, in which the level of water 
diffusion limitation in the tissue is assessed. Neuroen-
docrine tumours, particularly those with a high con-
nective tissue content, cause limitation of the diffusion 
of water molecules, which generates intense signals in 
the DWI sequence, accompanied by lowered ADC. DWI 
is particularly valuable in tumours with a significant 
connective tissue component, which are poorly or atypi-
cally enhanced after intravenous administration of the 
contrast agent [6, 76, 105].
It seems that well-differentiated PNETs represent 
higher values in ADC maps than PNECs [6].
2.4. Radioisotope diagnostics of PNENs
The recently observed development of diagnostic 
methods with the use of somatostatin receptor imaging 
(SRI), also in combination with intraoperative detection 
with the use of isotope probe, contributes to higher 
detection rates of PNENs and their metastases. These 
tests can identify lesions undetected by anatomical 
imaging methods, increasing the chances of locating 
the primary focus and determining the actual stage of 
the neoplasm [6, 107–109]. They may also be the first-
line method in the diagnostics of early recurrence, in 
monitoring the disease, and in choosing a suitable treat-
ment. A positive result of receptor scintigraphy is also 
the basis for introducing a therapy with a somatostatin 
analogue (SSA) [6, 108, 110]. SPECT/CT with the use 
of 99mTc-labelled somatostatin analogues is still used in 
the diagnostics of PNENs, although the optimal  radi-
olabelled somatostatine analogues examination is PET/ 
/CT with the use of 68Ga-radiolabelled somastostatine 
analogues, to enable a complete assessment of the stage 
and extent of the disease [111–113]. The sensitivity of 
somatostatine analogues PET/CT in the case of PNENs 
ranges from 86 to 100%, and the specificity ranges be-
tween 79 and 100% [113–118], excluding insulinoma, 
for which the estimated sensitivity is lower. PET/CT 
examination using 68Ga-somatostatine analogues may 
affect the management in 13–71% of patients; therefore, 
it should be a standard procedure in patients with 
PNENs (considering the slightly lower sensitivity of 
the test in insulinoma) [118, 119].
Other tracers that can be used in the diagnostics of 
PNENs include: 18F-DOPA, especially if the SRI examina-
tion results are negative [120, 121], 11C-5-hydroxytryp-
tophan [121],18FDG (in the diagnostics of fast-growing, 
aggressive PNENs and NECs with poor prognosis) 
[122, 123], and labelled glucagon-like peptide analogues 
[125–127]. Due to the very high expression of recep-
tors for GLP-1 in some neoplasms, estimated at nearly 
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100% in benign insulin-secreting tumours, scintigraphy 
with the use of labelled GLP-1 analogues may become 
a diagnostic method competing with SRI [110, 125, 126].
The next step to improve sensitivity of location diag-
nostics of small PNETs (gastrinoma, insulinoma) is using 
an intraoperative radioisotope probe (RGS) [6, 127, 128].
2.5. Location diagnostics of different PNENs
2.5.1. Insulinoma
Most frequently these are small tumours, less than 
2 cm in diameter (60–70% of cases), usually classified as 
Group 1 according to the WHO classification; they are 
mostly single (85%) and in 99% of cases are located in 
the pancreas, with a similar prevalence for all parts of 
the organ [6, 23]. While conducting location diagnostics 
in the search for the cause of hypoglycaemia with hy-
perinsulinism, it should be noted that in approximately 
4% of cases the reason is hyperplasia of β cells (nesidi-
oblastosis; NIPHS, non-insulinoma pancreatogenous 
hypoglycaemia). In the case of insulinoma, the most 
sensitive imaging examinations include EUS and USG. 
The usefulness of classical USG, EUS, IOUS, CT, and 
MRI is discussed in detail in the section concerning the 
imaging diagnostics of pancreatic tumours.
Another test used in the diagnostics of insulinoma is 
SRI. It is important to note that only some insulinoma 
tumours demonstrate somatostatin receptor expression 
(according to literature, the frequencies of expression 
for different SSTR types in insulinoma are as follows: 
SSTR1 — 51%, SSTR2 — 69%, SSTR3 — 62%, SSTR4 — 
39%, SSTR5 — 66%) [6, 107]. If the results of other imag-
ing tests are negative, a PET/CT scan may be performed 
with 68Ga-somatostatin analogue 68Ga-DOTATOC, and 
68Ga-DOTATATE (the sensitivity of a test with labelled 
68Ga DOTANOC and DOTA-Nal3-Octr is relatively low 
[25–31%]) [112, 129]. Where PET techniques are not 
available, an examination with Tc99m-labelled SSA can 
be performed (SPECT/CT).
In insulinoma it is also possible to use angiography 
with selective arterial calcium injection; however, this 
test is performed very rarely [130–132]. The method 
can be used if other imaging techniques do not enable 
locating of the focal lesion [23]. In the near future, GLP-1 
analogue will probably play an important role in the 
diagnostics of small, difficult-to-detect insulinomas [6, 
124–126].
2.5.2. Gastrinoma
The tumour is discussed in detail in the section on 
gastro-duodenal NENs.
A gastrinoma is typically to be found within the 
triangle of the pancreatic head — duodenum — he-
patic hilum. In 48–60% of cases, lymph nodes and 
hepatic metastases are present at the diagnosis, but in 
some groups of patients the proportion of malignant 
tumours is up to 90% [6, 135]. Multifocal lesions are also 
possible. The usefulness of USG, EUS, intraoperative 
USG, IOUS, CT, and MRI examinations are presented 
in the section concerning the imaging diagnostics of 
pancreatic tumours.
Other examinations used for the diagnostics of 
gastrinoma include SRI. The sensitivity of gastrinoma 
detection according to different authors ranges between 
50 and 100% (the literature data reveal the following 
frequencies of expression for individual receptor types: 
SSTR1 — 71%, SSTR2 — 50%, SSTR3 — 92%, SSTR4 — 
78%, and SSTR5 — 81%) [6, 134]. SRI is the best exami-
nation to assess the early stages of the disease and the 
presence of distant metastases, but the sensitivity of the 
test decreases to 50% if the tumour is smaller than 1 cm 
[6, 112, 135]. The preoperative staging should involve 
at least SRS, and preferably a PET/CT examination 
with the use of 68Ga-somatostatine analogues [8, 136]. 
If PET/CT is available, it should be the first-line im-
aging diagnostic test [113], and, where it cannot be 
conducted, SRS/SPECT in combination with EUS and 
oesophagogastroduodenoscopy should be performed. 
In the case of rapidly progressing NETs of G1/G2, a PET/ 
/CT examination with 18FDG should be considered [122].
In the future, the diagnostics of gastrinoma could in-
clude scintigraphy with GLP-1 analogue, due to GLP-1 
receptor expression on the surface of this tumour.
In the location diagnostics of small tumours, the 
combined use of several diagnostic methods seems 
reasonable, and in certain cases also performance of 
an angiography (the sensitivity of angiography is esti-
mated at 30–50%). In the case of a gastrinoma located 
in the duodenum, intraoperative transluminescence is 
also used [6].
2.5.3. Location diagnostics for glucagonoma,  
VIPoma, somatostatinoma, non-functional tumours, 
and ACTHoma
At the moment of diagnosis, glucagonoma, somatostati-
noma, and non-functional tumours are usually large (ap-
proximately 5–6 cm), whereas VIPoma is slightly smaller 
(approx. 2 cm). The lesions are usually diagnosed late, 
and in approximately 70–90% of cases metastases are 
found already at the diagnosis [6, 26, 134]. Due to the 
size of the lesions, they are easier to find by means of 
classical imaging methods (USG, CT, MRI). SRI, whose 
diagnostic sensitivity is 70–100%, is a standard exami-
nation in the assessment of primary lesions and clini-
cal staging (detection of metastases to the liver, lymph 
nodes, adrenal glands, spine), and in qualification for 
receptor radiotherapy [6, 26, 135]. SSTR1 and SSTR2 
expression is observed mostly in glucagonoma, SSTR5 in 
somatostatinoma, SSTR2 in VIPoma, and SSTR1, SSTR2, 
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SSTR3, and SSTR5 in non-functional neoplasms. Rare 
ACTHoma neoplasms also demonstrate somatostatin 
receptor expression. In the case of rare functional pan-
creatic tumours, EUS is not recommended as the first-
line procedure, but it may be used when the MDCT, MRI, 
and SRI results are inconclusive. EUS may be useful in 
pre-operative diagnostics, whereas it is rarely necessary 
in patients with hepatic metastases [6, 9].
2.5.4. Pancreatic endocrine carcinomas
In the location diagnostics of poorly differentiated, fast-
growing PNENs, as well as NECs and their metastases, 
all imaging examinations may be used: USG, CT, MRI, 
18FDG PET/CT, and SRI in tumours with overexpression 
of somatostatin receptors [6].
Minimal consensus statement on imaging and radio-
isotope examinations:
In the diagnostics of pancreatic neuroendocrine neo-
plasms, both classical imaging techniques and nuclear medi-
cine tools are used.
In non-functional PNENs:
— multiphase CT and MRI are the basic tests,
— another SRI examination.
In functional PNENs:
— SRI,
— Next examination is EUS and multiphase CT/MRI.
The EUS examination should be performed in each case 
of a clinically diagnosed functional tumour, and if there are 
indications for a biopsy.
In pancreatic NECs and in the case of fast-growing 
PNETs, in individual clinical cases, 18FDG PET/CT can be 
used (*evidence level 3).
3. Treatment
3.1. Surgical treatment
3.1.1. Surgical treatment of well-differentiated pan-
creatic NETs of G1/G2
General principles
Surgical treatment is the therapy of choice in the case 
of PNENs because it is associated with significantly 
prolonged patient survival [8]. The development of dia-
gnostic methods has improved the detection of small, 
asymptomatic, incidental NF-PNETs [136, 137] (*evidence 
level 3). Most non-functional neoplasms ≤ 2 cm in di-
ameter are benign and demonstrate a moderate risk of 
becoming malignant. In certain cases, tumours ≤ 2 cm 
in diameter, diagnosed accidentally, may be observed. 
This applies to asymptomatic G1 or G2 tumours with 
low Ki-67%, especially those located in the head of the 
pancreas, if malignancy is not suspected on the basis of 
a radiological examination, and after consideration of 
individual patient characteristics (age, patient’s decision, 
comorbidities) [11]. Due to the lack of clear recommen-
dations, the decision on the course of treatment should 
be taken by a multidisciplinary team of doctors experi-
enced in the management of PNETs (*evidence level 4). 
When choosing a surgical treatment, it is necessary to 
consider the early and long-term effects of this therapy. 
According to the WHO classification, there is a correla-
tion between tumour size and its potential malignancy. 
Tumours > 2 cm, depending on their characteristics, 
require a pancreatic parenchyma-saving or an extensive 
resection (*evidence level 3) [11]. Symptomatic tumours, 
regardless of their size, usually require a resection.
In MEN-1, if multiple lesions occur, it is recom-
mended to remove them preventively before they 
become malignant; however, this approach in the case 
of small, non-functional tumours is still controversial 
(*evidence level 3) [6, 8]. The presence of numerous 
nodules sometimes requires a whole-organ resection. 
It is known that non-functional tumours associated 
with MEN-1 should be removed if they are over 2 cm 
in diameter, metastatic, and fast-growing (increase of 
> 0.5 cm per year) [11] (*evidence level 3).
The type of surgical treatment for PNET depends 
on its size, location, invasion of the adjacent organs, 
presence of distant metastases, the patient’s gene-
ral condition, and the ability to control the clinical 
symptoms (*evidence level 4). Patients are qualified 
for a radical or palliative treatment, which only im-
proves the quality of life (*evidence level 4). In the 
case of tumours located in the head of the pancreas, 
pancreatoduodenectomy is performed; whereas in 
tumours located in the body or tail of the pancreas, 
circumferential resection is conducted, with or with-
out splenectomy (*evidence level 4). In certain cases of 
small and well-demarcated PNETs, atypical resections 
may be performed, including enucleation and resec-
tion of the middle segment, also using a laparoscopic 
technique (*evidence level 3) [138, 139]. Resection of the 
middle segment is performed primarily in the case of 
small lesions located in the pancreatic body. In cer-
tain cases, central pancreatectomy is performed with 
a Roux-en-Y anastomosis of the pancreatic tail with 
a loop of the small intestine, and closing off the body 
of the pancreas. The condition of tumour enucleation 
is continuity of the duct of Wirsung [8]. Resection is 
necessary if the tumour is located < 3 mm from the 
pancreatic duct [9]. Enucleation of the lesion entails the 
risk of damaging or closing the duct of Wirsung, which 
is associated with complications [140]. These include 
acute postoperative pancreatitis and pancreatic fis-
tula. Apart from the above complications, resection of 
a large part of the pancreas may cause the symptoms 
*evidence level according to OCEMB [252]
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of exocrine and endocrine pancreatic insufficiency [141]. 
Tumour resection should be considered even in the 
presence of metastases, including hepatic metasta-
ses, if they are potentially resectable, and the patient 
meets the criteria for the surgery (*evidence level 4) 
[7, 142]. As pancreatic tumours are often malignant, it 
is necessary to remove the regional lymph nodes dur-
ing resection (*evidence level 3) [7, 141, 143]. In the case 
of enucleation and resection of the middle segment, 
it is also recommended to remove lymph nodes for 
histopathological examination [8, 140]. It is generally 
believed that G3 PNETs should not be operated on if 
disseminated metastases were found in the diagnostic 
process (*evidence level 3) [7]. Resection should be per-
formed only in those centres specialising in surgery of 
the pancreas. In the case of PNET, an intraoperative 
USG examination is recommended.
Currently, laparoscopic resection of the pancreas is 
increasingly common, but the decision concerning the 
use of the “open” or laparoscopic method should be 
taken by a pancreatic surgery specialist in the referen-
tial centre (*evidence level 3). Circumferential resections 
and laparoscopic enucleation of pancreatic tumours are 
currently considered to be safe.
The most common functional tumours are insu-
linoma and gastrinoma, whereas other tumours are rare 
(RF-PNET, rare functional pancreatic neuroendocrine 
neoplasms) [9].
Gastrinoma, Zollinger-Ellison syndrome (ZES)
A gastrinoma is most often located in the head of the 
pancreas; in 60–90% of cases it is a malignant neoplasm, 
and due to the frequent invasion of the lymph nodes 
there are indications for regional lymphadenectomy 
[6, 144]. It is recommended that the lesion be removed 
radically to prevent hepatic metastases, which consider-
ably worsen the prognosis. The scope of the procedures 
depends on the tumour location and size, and compris-
es enucleation, resections of the middle segment, distal 
resections, and pancreatoduodenectomies [6, 143].
The role of surgical treatment in patients diagnosed 
with ZES without MEN-1, and with negative results 
of the pre-operative imaging tests (no visualisation) 
is disputable [6, 11]. A recent study revealed that 
all patients with sporadic ZES benefit from surgical 
exploration with the intent to treat. This applies both 
to patients with tumours visualised during imaging 
tests before the surgery, and to those whose tumours 
were not shown in pre-operative imaging examina-
tions [145] (*evidence level 3). This study demonstrated 
a higher rate of tumour-free individuals after resection, 
and a higher 20-year survival rate among the patients 
with negative results of the imaging examinations 
than in those with positive results. Tumours were 
detected in > 98% of patients, regardless of tumour 
visualisation or lack thereof in imaging examinations. 
Therefore, in the case of all patients with ZES without 
MEN-1, who do not present medical contraindications 
for the procedure, it is recommended that surgical 
exploration be performed by a surgeon experienced 
in the treatment of neuroendocrine tumours [11] 
(*evidence level 3). As gastrinomas are often multiple 
tumours and occur in the duodenum, careful examina-
tion of the abdominal cavity and pancreatoduodenal 
field during the surgery is recommended, possibly 
including a duodenotomy [11].
Apart from the prognostic value of lymph node 
metastases, studies on gastrinoma revealed that lym-
phadenectomy may extend survival [146, 147] (*evidence 
level 3). This supports the idea of removing lymph 
nodes in the tumour area during every surgery involv-
ing gastrin-secreting tumours. Surgical resections of 
tumours with angioinvasion are controversial. Recent 
reports on resectability in 91% of cases with 10-year 
survival rates of 62% support the claim that surgical 
resection should be considered also in patients with 
PNETs, who demonstrate, under pre-operative exami-
nations, tumour pressure on vessels or angioinvasion, 
and the decision should be taken by a team of specialists 
[11, 148, 149] (*evidence level 3).
In Zollinger-Ellison syndrome, which is a part of 
MEN-1 syndrome, in the case of NF-PNETs or a tumour 
≤ 2 cm in diameter, surgical treatment is not typically 
recommended. Surgical therapy is indicated if the tu-
mour size is over 2 cm. This approach is intended to 
prevent metastases [142] (*evidence level 3). According 
to some authors, pancreatoduodenectomy is the recom-
mended procedure (for tumours located in the head 
of the pancreas) because less extensive procedures 
are associated with recurrence in 90% of cases [9, 144]. 
However, current routine management does not in-
clude PD, and enucleation remains the recommended 
surgical procedure [11].
In MEN-1/ZES patients with numerous, small 
gastrin-secreting tumours and metastases to the 
lymph nodes, only an extensive surgery, such as 
pancreatoduodenectomy or complete resection of the 
pancreas, forms a curative procedure. However, these 
procedures are not recommended currently as standard 
management, due to possible early and long-distance 
complications, the fact that patients with PNETs ≤ 2 cm 
in diameter demonstrate good long-term prognosis 
(even 100% survival rate after 15 years of observation), 
and the possibility to control excessive secretion of 
gastric juice in MEN-1/ZES patients with pharmacol-
ogy [9, 11, 150].
*evidence level according to OCEMB [252]
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Minimal consensus on surgical treatment of gastrin-
secreting tumours
 — All patients with sporadic gastrin-secreting tumours, 
who do not present
 — contraindications for surgical procedure, should un-
dergo
 — surgical exploration performed by a surgeon experienced 
in the treatment of
 — neuroendocrine tumours [145].
 — During every surgery of gastrinoma, lymph nodes in 
the tumour area should be removed, as this demonstrates 
a prognostic value and can increase the rate of cured cases.
 — Surgical resection should be considered by a team of ex-
perienced surgeons in
 — PNET patients who demonstrate tumour pressure on ves-
sels or angioinvasion in the pre-operative examinations.
 — In patients with MEN-1/ZES with PNET ≤ 2 cm in 
diameter, or in whom NF-PNET
is visible in the imaging tests, routine surgical explora-
tion is not commonly recommended. In patients with PNETs 
> 2 cm in diameter, enucleation remains the recommended 
surgical procedure, and pancreatoduodenectomy is reserved 
for individual, selected cases [9, 150].
Insulinoma
Insulinomas are benign in 90% of cases; their removal 
does not require regional lymphadenectomy and, where 
the precise preoperative location of the tumour is known, 
laparoscopy is effective [6, 151] (*evidence level 1).
In most cases, enucleation of an insulin-secreting 
tumour is possible, whereas in others more extensive 
resection is required [152] (*evidence level 1). In the case 
of a suspected malignant insulinoma or recurrence of 
the tumour, radical treatment is recommended, includ-
ing excision of the recurrence and any possible hepatic 
metastases [9]. Endoscopic or percutaneous ablation 
therapies have also been described. In the case of in-
sulinoma, both in patients with sporadic tumours and 
with MEN-1, EUS-controlled ablation with ethanol, 
or RFA controlled by CT control or other visualisation 
methods, was effective [152] (*evidence level 1). It has been 
documented that, following EUS-controlled alcohol ablation, 
patients remain free from disease symptoms for many years 
[6, 153].
Minimal consensus on surgical treatment of insulin-
secreting tumours
 — A surgical procedure is recommended in all patients with 
insulin-secreting tumours with
 — or without the presence of MEN-1 syndrome, with the 
exception of non-resectable metastatic tumours.
 — Laparoscopic procedures are recommended in patients 
with sporadic tumours and tumours found in imaging 
examinations [154].
 — In patients who are not eligible for surgical treatment, 
cases of ablation therapy using endoscopic or percutaneous 
methods were described for insulinoma [152].
Rare (RF-PNETs) and very rare functional tumours
In this group of tumours, radical treatment is recom-
mended, and the scope of resection and lymphadenec-
tomy corresponds to that performed due to gastrinoma.
Minimal consensus on surgical treatment of RF- 
-PNETs
 — Resection with the intent to treat remains the recom-
mended option in all patients
 — with rare or very rare functional PNETs, with the excep-
tion of patients with non-resectable metastatic lesions [9].
 — Laparoscopic methods can be used in RF-PNETs visible 
in imaging examinations [9, 139].
 — In patients with MEN-1 with PNET ≤ 2 cm in diameter 
or NF-PNET found in imaging tests, routine surgical 
exploration is still not generally recommended. In patients 
with PNETs > 2 cm in diameter, enucleation/Local intra-
operative resection remains the generally recommended 
surgical procedure to perform, while pancreatoduodenec-
tomy is reserved for special, individual cases.
Surgical treatment versus observation of NF-PNETs
Some studies have assessed the safety and possibility 
of the non-operative treatment of asymptomatic, spo-
radic NF-PNETs ≤ 2 cm in diameter, particularly in cases 
which would otherwise require extensive resections 
[11, 155–157] (*evidence level 3). According to most 
authors, a conservative approach seems to be a safe 
option because most of the observed tumours did not 
reveal any significant changes in the follow-up period 
[155, 158] (*evidence level 3). However, some studies 
demonstrated that tumours < 2 cm may invade the 
lymph nodes and can be associated with distant me-
tastases [157, 159–163] (*evidence level 3). According to 
some authors, a change in the size of tumours, which 
can be safely left for observation, should be considered, 
from ≤ 2 cm to ≤ 1.5–1.7 cm [160, 162] (*evidence level 3).
Advanced F-PNETs
In advanced functional PNETs, resection is intended to 
reduce the symptoms and the tumour mass. Cytoreduc-
tion may be considered if removal of over 90% of the 
tumour mass is possible, even if hepatic metastases are 
present [164] (*evidence level 3). Removal of 90% of the vis-
ible tumour mass is possible in only 5–15% of cases [165]. 
Cytoreduction may be performed with radiofrequency 
thermoablation (RFA) (*evidence level 3), which can also 
be conducted laparoscopically or percutaneously under 
CT control. This method may be used if the number of 
focal lesions in the liver is lower than 10, and the largest 
*evidence level according to OCEMB [252]
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one is < 5 cm in diameter (optimally 3 cm). This method 
enables the control of symptoms in over 90% of patients 
[166]. Radical excision of hepatic metastases is the 
“golden standard” in the therapy of advanced PNETs; 
therefore, resection should be performed whenever 
possible (*evidence level 4). The method of resection 
depends on the patient’s general condition, the size, 
location, and number of metastases, and whether it 
comprises enucleation, wedge excision of a fragment 
of the liver, excision of a segment(s), non-anatomical 
resection, or hemihepatectomy. R0 resection should 
be the target in the case of removal of hepatic metas-
tases. Cytoreductive procedures are acceptable [167, 
168] (*evidence level 2). Resective treatment of hepatic 
metastases of PNETs is considered only in NETs of 
G1 and G2 [164] (*evidence level 3). It depends on the 
resectability of the lymph nodes, lack of micronodular 
or non-resectable dissemination in the peritoneum, or 
distant metastases outside the abdominal cavity [169]. 
Recent studies emphasise the significance of simultane-
ous surgical resection of advanced primary PNETs with 
hepatic metastases, and the associated low number 
of deaths and post-operative complications [148, 170] 
(*evidence level 3). However, simultaneous pancrea-
toduodenectomy and extensive hepatectomy should be 
avoided due to the high number of complications [170]. 
Excision of the primary tumour, lymph nodes, and 
hepatic metastases, combined with thermoablation, 
may reduce the tumour mass by more than 90% [169]. 
In the case of unresectable metastatic lesions in the 
liver, cholecystectomy should be performed during 
surgery to prevent ischaemic complications of the 
gallbladder resulting from possible implementation 
of (chemo) embolisation. Resection of hepatic lesions 
may be performed in one or two stages, depending 
on the location and size of the metastases [140]. Other 
methods for the treatment of metastases include so-
called locoregional therapies (variants of ablation, 
embolisation) and liver transplantation. It is assumed 
that transplantation is conducted in selected groups of 
patients with exacerbated symptoms associated with 
hormonal secretion. Patients who may benefit from 
transplantation are those under the age of 50 years, 
without metastases outside the liver, and with a low 
expression of Ki-67 [143].
If resection of hepatic metastases is impossible, the 
recommended palliative treatment methods include 
selective hepatic artery embolisation (HAE), transarte-
rial chemoembolisation (TACE), or embolisation with 
the use of a radioisotope (*evidence level 3). Currently, 
these methods are considered to be safe [82, 149]. RFA, 
cryoablation, and microwave ablation (MWA) can be 
used for tumours ≤ 5 cm [165].
Resection of a resectable stage IV primary tumour is 
under consideration [171] (*evidence level 3). In certain 
cases of unresectable hepatic metastases, macroscopic 
intraperitoneal lesions may also be removed during the 
primary tumour resection, so that further treatment 
stages do not concentrate primarily on the liver [172]. 
There is no consensus on the simultaneous resection of 
hepatic and intraperitoneal lesions [173]. If extensive 
surgery of the liver with the resection of peritoneal le-
sions is necessary, dividing the procedure into stages, 
conducting the resection in a specialist centre, and 
introducing multidirectional treatment should be con-
sidered [174]. Currently, the combination of surgery 
and perioperative intraperitoneal chemotherapy, as 
well as intraoperative hyperthermic intraperitoneal 
chemotherapy (HIPEC), are in the experimental phase 
[172, 173].
If tumour resection is not possible, a palliative 
surgical management is implemented, which can 
significantly affect the quality of life. It is used after 
exhausting all non-surgical methods, mainly if the 
tumour is responsible for mechanical jaundice, chronic 
pain and gastrointestinal obstruction or bleeding. The 
treatment method is individualised for each patient. 
If mechanical jaundice occurs, it is recommended 
that anastomosis between the bile duct and intestine, 
or draining of the bile tract, be performed. When an 
unresectable pancreatic tumour disturbs the passage 
of food through the duodenum, bypass surgery is 
recommended, usually gastrointestinal anastomosis. 
The method of surgical management of chronic pain is 
coeliac plexus neurolysis and/or thoracoscopic section 
of the splanchnic nerve.
Due to the limited number of studies conducted, 
no recommendations are available for patients with 
PNENs of unknown original site. In one of the studies 
the authors emphasise the significance of a surgical 
procedure in order to locate the primary tumour site, 
together with aggressive cytoreduction of the metasta-
ses, which could enable estimation of the survival and 
justification of the procedures [175] (*evidence level 3).
Treatment of patients with PNETs should be com-
prehensive and conducted by a multidisciplinary team 
of doctors; the surgery should be performed in a centre 
specialising in pancreatic surgery (*evidence level 3) [142].
Minimal consensus statement on surgical treatment
 — Accidentally detected, asymptomatic, non-functional 
neoplasms ≤ 2 cm in diameter, without evidence of histo-
pathological and radiological malignancy may be observed, 
and the decision on the course of treatment should be taken 
by a multidisciplinary team of doctors experienced in the 
management of PNETs. Tumours > 2 cm require surgery, 
usually with lymphadenectomy.
*evidence level according to OCEMB [252]
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 — In certain cases of small (< 2 cm) and well-demarcated 
PNETs, atypical resections may be performed, including 
enucleation and resection of the middle segment (it is 
necessary to collect the lymph nodes for histopathological 
examination). Circumferential resections and enucleations 
may be performed laparoscopically.
 — Tumour resection should be considered even in the pres-
ence of metastases, including hepatic metastases, if they 
are potentially resectable and the patient meets the criteria 
for the surgery.
 — It is believed that PNECs should not be operated on if dis-
seminated metastases were found in the diagnostic process.
 — In advanced functional PNETs resection is intended to 
reduce the symptoms and the tumour mass. Cytoreduc-
tion may be considered if removal of more than 90% of 
the tumour mass is possible, even if hepatic metastases 
are present (*evidence level 3).
 — In the case of unresectable hepatic metastases, the recom-
mended palliative treatment includes HAE, TACE, or 
embolisation with the use of a radioisotope. RFA, cryo-
ablation, and MWA can be applied in tumours ≤ 5 cm 
(*evidence level 3).
 — Liver transplantation is conducted in selected groups 
of patients with exacerbated symptoms associated with 
hormonal secretion. Patients who may benefit from trans-
plantation are those under the age of 50 years, without 
metastases outside the liver, and with a low expression of 
Ki-67 (*evidence level 3).
3.1.2. Surgical treatment of neuroendocrine  
neoplasms G3 NET and NECs
G3 NETs and NECs are very rare neoplasms, account-
ing for less than 1% of gastrointestinal malignant 
neoplasms. In up to 85% of cases, metastases are found 
at the moment of diagnosis (with distant metastases 
in 65% of cases) [37, 176]. Surgical treatment with 
the intent to treat is usually conducted in cases of lo-
cally advanced disease, where the chances of cure are 
limited [177]. According to present guidelines, in an 
advanced, metastatic disease, reduction of the tumour 
mass (cytoreductive surgery) and surgical resection 
of the metastases are not recommended [177]. The 
ablative therapy of metastases to liver are also not 
recommended [177].
According to other authors, aggressive locoregional 
therapy comprising surgery, RFA, and intrahepatic in-
tra-arterial therapies is justified and safe in patients with 
GEP NETs of G3 and hepatic metastases: it improves 
the treatment outcomes [178, 179] (*evidence level 3). 
The varied effectiveness of surgical treatment can be 
explained by the heterogeneous nature of G3 neuroen-
docrine neoplasms, which can be further classified on 
the basis of their biological characteristics.
3.2. Endoscopic treatment of PNENs
The treatment of PNENs is generally surgical, and en-
doscopic management is only symptomatic [6].
Endoscopy can be used for the symptomatic treatment of:
 — mechanical jaundice (prosthesis of the biliary duct),
 — obstruction of the gastrointestinal tract (prosthesis 
of the gastrointestinal tract lumen),
 — control of gastrointestinal bleeding (the use of en-
doscopic haemostatic methods),
 — pain (coeliac plexus neurolysis).
EUS-controlled coeliac plexus neurolysis (CPN), 
described for the first time in 1996, involving adminis-
tration of 0.25% bupivacaine solution, followed by 98% 
alcohol, is an alternative method for the management of 
chronic pain associated with pancreatic tumours [6, 180].
It is also possible that in the future endoscopic EUS- 
-controlled ablation of pancreatic NETs, involving the 
administration of cytotoxic agents or alcohol [181–184], 
or using thermoablation [185, 186], will become a mini-
mally invasive therapeutic method for patients who 
cannot be treated surgically (evidence level 4).
3.3. Systemic therapy
Therapeutic management of patients with advanced 
non-resectable locoregional disease and/or distatnt 
metastases, or with generalised disease, should be 
determined by a multidisciplinary team of specialists, 
following the idea of the ENETS Centre of Excellence.
The choice of systemic therapy  depends on the 
symptoms, staging of the disease, the level of radi-
otracer uptake in receptor scintigraphy, and histological 
characteristics of the tumour, as well as the patient’s 
general condition and comorbidities [6].
Systemic treatment involves therapy with “cold” 
SST analogues (octreotide, lanreotide), molecularly 
targeted treatment (everolimus, sunitinib), and therapy 
with cytostatics, as well as a combination of the above.
3.3.1. Somatostatin analogues
Functional pancreatic neuroendocrine neoplasms  
(F-PNENs)
Somatostatin analogues (octreotide, lanreotide) are firt-
line therapy in functional PNENs, regardless of the tu-
mour size [7, 187] or tumour grading and stage of disease, 
to control the symptoms secondary to excessive hormone 
secretion, prior to a surgical therapy or inadvanced stage. 
In case of a refractory syndrome, dose escalation  above 
the maximum registered dose, or shortenig the interval 
between the doses may be the option. Increasing the 
dose consists of reducing the intervals between injections 
of long-acting SSAs, from four to three weeks (to two 
weeks in clinical studies) [188, 189]. Use of pasireotide, 
a new SSA, can be considered in a treatment-resistant 
*evidence level according to OCEMB [252]
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carcinoid syndrome, if all other therapeutic options have 
failed, including ablation, TAE, and interferon alpha, 
and receiving the treatment as part of a clinical study 
is not possible.
Effect of SSAs in functional GEP NENs is discussed in 
“Diagnostic and therapeutic guidelines for gastro-entero- 
-pancreatic neuroendocrine neoplasms (recommended 
by the Polish Network of Neuroendocrine Tumours)” (see 
p. 79–110), and below in Pharmacotherapy in selected 
functional PNETs.
Non-functional pancreatic NENs (NF-PNENs)
The first-line therapies in GEP NETs are SSAs, which 
have demonstrated antiproliferative effects in prospec-
tive phase III studies (CLARINET) [190–192].
Somatostatin analogues can be recommended in 
systemic treatments as a first-line therapy in pan-
creatic NETs with a low proliferation index (Ki-67 
< 10%), due to their antiproliferative effect and lim-
ited toxicity, considered a class effect of SSAs. CLARI-
NET provides direct evidence for the antiproliferative 
effect of lanreotide Autogel at a dose of 120 mg every 
four weeks, in PNETs, whereas there are no prospec-
tive, randomised studies on the use of octreotide 
LAR in pancreatic NETs. SSAs may be recommended 
to prevent the growth of the tumour, or inhibit it 
in the case of PNET. Simultaneously, based on the 
CLARINET study methodology, using lanreotide in 
the treatment of entero-pancreatic NETs of G1 and G2 
is recommended up to a Ki-67 of 10%, regardless of 
the level of hepatic tumor burden [193]. However, re-
garding all NENs, no experts have yet determined any 
particular limit value for recommendation of SSAs in 
antiproliferative therapy. An assessment in a prospec-
tive study is required to determine the proper Ki-67 
value to make the choice between SSAs and more ag-
gressive therapeutic methods. Using lanreotide is re-
commended in patients with PNETs, regardless of the 
level of hepatic tumor burden, which is supported by 
the subgroup analysis in the CLARINET study [193]. 
Although the study did not demonstrate a benefit in 
overall survival because the subjects were allowed to 
cross-over from the placebo group to the open-label 
lanreotide group after progression, it is expected that 
lanreotide improves final outcomes of the treatment 
in patients with PNETs [194]. Therapy should start 
immediately after the diagnosis in cases of:
 — a significant degree of hepatic tumor burden and 
extensive neoplastic lesions (they are the most im-
portant prognostic factors) [195];
 — a primary tumour location in the pancreas (five-year 
overall survival in stage IV patients does not exceed 
40–60%) [11, 196].
Despite a similar mechanism of action and com-
parable effectiveness of both SSAs (i.e. octreotide and 
lanreotide), the effect of octreotide on the control of the 
neoplastic process in PNETs has not been confirmed in 
a phase III study. However, it seems that, considering 
the conclusions from retrospective analyses indicating 
its effectiveness in this location, and indirect conclu-
sions from the RADIANT-1 study, octreotide can be an 
acceptable therapeutic option in the antiproliferative 
treatment of PNETs [197, 198].
There is no data to support continued use of SSA 
therapy if the disease progresses during the treatment 
with the SSA (however, the therapy may be necessary to 
maintain the inhibitory effect on the secretion of bioactive 
substances/hormones in the case of functional tumours).
Minimal consensus statement on the treatment with 
somatostatin analogues
Octreotide and lanreotide are effective in controlling 
clinical syndromes in functional NETs, and demonstrate an 
antiproliferative effect in well-differentiated NETs.
In PNETs, the antiproliferative action of the SSA is used 
both in the period of stabilisation, and progression of the di-
sease. SSAs can be considered the first-line therapy for PNETs 
with a low proliferative index up to a Ki 67 of 10%. Although 
the antiproliferative effectiveness of both available SSAs is 
considered a class effect, the scientific evidence supporting the 
use of lanreotide in the treatment of pancreatic NETs of G1 
and G2, regardless of hepatic tumor burden, is more reliable.
Pharmacotherapy in selected functional PNETs
Insulinoma
Pharmacological treatment of insulinoma is intended to 
prepare patients for a surgical procedure, or to achieve 
biochemical control in patients with an inoperable meta-
static tumour. Apart from frequent meals of small volume, 
patients require intravenous glucose administration. 
Despite this treatment, hypoglycaemia often requires 
additional medications to control the serum glucose 
concentration. In most insulinoma patients, diazoxide 
proved to be effective in managing the symptoms of 
hypoglycaemia [11]. Diazoxide is used as a short-term 
treatment for patients with insulinoma awaiting surgery, 
or as a long-term treatment for patients with inoperable 
tumours. The recommended daily dose is 50–300 mg 
orally, maximally 600 mg/d. Usually this treatment is 
effective in controlling the symptoms of hypoglycaemia 
in patients with insulinoma. Adverse reactions, includ-
ing oedema, increased body weight, hirsutism, and renal 
function disorders are common but usually tolerable.
Diazoxide therapy is often supported with hydro-
chlorothiazide at a dose of 25 mg/day, which prevents 
oedema and hyperkalaemia, and increases the hyper-
glycaemic effect of diazoxide.
*evidence level according to OCEMB [252]
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Verapamil and diphenylhydantoin (phenytoin) can 
be used to control glycaemia in some patients with 
insulinoma. Corticosteroids, including prednisolone, 
are also used in patients with insulinoma presenting 
refractory hypoglycaemia.
Somatostatin analogues (octreotide and lanreotide) 
are used in patients with confirmed expression of 
somatostatin receptors of type 2 on the tumour cells 
[199]. Approximately 30–50% of patients respond to 
SSAs, although this treatment  may be ineffective in the 
control of hypoglycaemia, and the condition of some 
patients may deteriorate during the therapy [200–206]. 
In certain cases hypoglycaemia may increase due to 
inhibited glucagon secretion [9, 207].
In patients with malignant insulinomas, the medi-
cations used to control insulin secretion and hypo-
glycaemia include everolimus, mTOR inhibitor [9], 
effective in controlling hypoglycaemia in patients with 
malignant insulin-secreting tumours [200, 201, 203, 205, 
208]. Sunitinib was also demonstrated to be effective in 
some patients.
Gastrinoma
Pharmacological treatment of gastrinoma is discussed 
in the section on gastroduodenal NENs (see p. 138–153).
VIPoma (symptoms: watery diarrhoea, hypoka-
laemia, achlorhydria [WDHA], Verner-Morrison syn-
drome): [6]
Hydration and supplementation of electrolytes are 
recommended because they may considerably improve 
the patient’s clinical condition. In patients with VIPoma 
and with a rare life-threatening syndrome, administra-
tion of SSAs significantly alleviates the symptoms. In 
patients with life-threatening diarrhoea, resistant to 
maximum SSA doses, corticosteroids are used.
Glucagonoma
Somatostatin analogues are the first-line medications.
Zinc salts may be used in patients with glucagonoma 
to prevent further skin damage. Antithrombotic proph-
ylaxis should be considered in all patients with NEN 
associated with an increased risk of thromboembolic 
complications (including glucagonoma).
Long-acting SSAs may be useful in patients with 
Cushing’s syndrome and acromegaly associated with 
the ectopic secretion of ACTH, PTHrP, or GHRH [147].
3.3.2. Molecularly targeted treatment (targeted 
therapy)
Currently, two molecular targeted drugs are available: 
m-TOR (mammalian target of rapamycin) pathway 
inhibitor, everolimus, and tyrosine multikinase inhibi-
tor — sunitinib. The above drugs demonstrate a con-
firmed antiproliferative activity in the case of advanced 
(non-resectable or metastatic) progressive pancreatic 
NETs of G1/G2. The disease progression within the last 
12 months should be assessed by radiological examina-
tion, according to the RECIST classification.
Based on the results of two placebo-controllod trials, 
a significantly prolonged  median progression-free sur-
vival (PFS) by about 5.5–6 months was demonstrated for 
both therapies. Remission rates were 5% for everolimus 
and about 10% in the sunitinib group [210, 211].
Everolimus is an oral medication, recommended in 
a daily dose of 10 mg, which effectiveness was demon-
strated in a clinical trials (RADIANT-1, RADIANT-3) 
involving patients with advanced, progressive G1/G2 
pancreatic NETs. The beneficial effect of everolimus 
therapy on PFS consisted primarily of disease stabi-
lisation or a small reduction in tumour mass and less 
frequent progression. In a subgroup analysis, the safety 
of everolimus in combination with octreotide was dem-
onstrated. The correlation between PFS and previous 
or current SSA therapy, or previous chemotherapy, was 
not shown [198, 210, 212].
Everolimus demonstrated effectiveness in the treat-
ment of insulinoma functional pancreatic tumours 
regarding control of glycaemia [213, 214], as well as in 
control of carcinoid syndrome symptoms (RADIANT-2) 
[215] and non-functional tumours (RADIANT-4) [216]. 
A similar hypoglycaemic effect was demonstrated in 
individual cases of PNETs treated with sunitinib [217]. 
Using targeted therapies in combination with SSAs in 
the treatment of functional NETs is a standard practice 
(inhibition of the tumour growth and improved control 
of the symptoms). Currently, clinical trials are being 
conducted comparing targeted treatment in combina-
tion with SSAs and monotherapy: targeted therapy vs. 
SSA (e.g. COOPERATE-2). The available data do not 
demonstrate benefits regarding PFS [218].
Using targeted therapies in combination with SSAs 
to obtain an antiproliferative effect in non-functional 
NETs requires further comparative studies.
Primary side effects associated with everolimus 
include mucositis, hyperglycaemia, and rare cases of 
non-infectious interstitial pneumonia.
Markedly increased toxicity was reported in patients 
previusly treated either with PRRT and/or chemo-
therapy [219].
Sunitinib is an oral medication, used at a daily 
dose of 37.5 mg, which effectiveness in the treatment 
of PNETs was demonstrated in a placebo-controlled, 
multicentre, randomised, phase III study (PFS 11.4 
vs. 5.5 months, HR 0.42; 95% CI 0.26–0.66, p < 0.001) 
[211]. The side effects associated with sunitinib include 
fatigue syndrome, arterial hypertension, and conges-
tive heart failure.
Targeted therapy is conducted until the disease 
progresses or unacceptable adverse events occur. Due 
to adverse reactions, dose reduction may be required 
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to 5 mg of everolimus per day or 25 mg of sunitinib per 
day [210, 211].
Due to a lack of direct comparative studies available 
(head-to-head) for these medications, the choice of 
targeted therapy is based on the medical history of the 
patient, comorbidities, the side effect profile, and avail-
ability of the treatment. The use of everolimus may be 
limited by comorbidities such as uncontrolled diabetes 
or lung diseases, and sunitinib therapy may be limited 
by serious cardiovascular complications.
Molecular targeted therapy may be used as first-line 
or second-line therapeutic options following chemo-
therapy or SSA therapy (cold or hot — PRRT). They 
should not be commonly used as first-line therapies, 
due to potential toxicity. There is no evidence allowing 
determination of a precise order for the various thera-
peutic options in the management of pancreatic NETs.
The best treatment sequence, considering survival, 
symptom control, and quality of life, is under discus-
sion, but remains controversial [220].
We are awaiting the results of a cross-over study 
(SEQTOR) assessing the antiproliferative effectiveness 
of everolimus compared against chemotherapy using the 
STZ/5-FU regimen in advanced pancreatic NETs [221].
At the moment, there is insufficient evidence sup-
porting the use of other targeted therapies, such as 
bevacizumab, sorafenib, pazopanib, or axitinib, in the 
treatment of pancreatic NENs [222–224].
Targeted treatment in NECs and NETs of G3.
There is no evidence supporting the use of targeted 
therapies in NECs and NETs of G3 (clinical trials in tractu 
www.clinical.trials.gov).
Minimal consensus statement on molecularly tar-
geted treatments:
 — Everolimus and sunitinib are registered antiproliferative 
drugs used in advanced pancreatic NETs (*evidence level 
1), and constitute one of many therapeutic options, along 
with SSAs and systemic chemotherapy.
 — Everolimus or sunitinib are recommended after a failure 
of SSA treatment, PRRT, or chemotherapy in pancreatic 
NETs of G1/G2. They can be considered as first-line thera-
pies, especially if SSAs cannot be used, or in the case of 
intolerance, or contraindications for chemotherapy.
 — Using targeted therapies in combination with SSAs in the 
treatment of functional NETs is a standard practice (inhibi-
tion of tumour growth and improved control of symptoms).
 — There is no evidence supporting the effectiveness of tar-
geted therapies in NECs and NETs of G3.
3.3.3. Chemotherapy
Chemotherapy (ChTh) is one of many therapeutic 
options for neuroendocrine neoplasms of pancreatic 
origin. Its place in the treatment algorithm depends on 
numerous factors, such as: histological characteristics 
of the neoplasm (differentiation, Ki-67%), significant 
tumor progression, the patient’s general condition, 
and internal diseases, as well as the patient’s prefer-
ence.
Adjuvant chemotherapy
In pancreatic NETs of G1 and G2, there are no indica-
tions for adjuvant therapy following radical treatment.
In the case of pancreatic NETs of G3 (comprising 
well-differentiated or moderately differentiated neo-
plasms with Ki-67 > 20%, according to the new clas-
sification from 2017), there is no evidence for the use 
of adjuvant treatment. In certain cases, the adjuvant 
therapy can be considered individually.
Pancreatic NECs — considering the high recurrence 
rate after radical surgical treatment, in the case of ag-
gressive neuroendocrine cancers, adjuvant chemother-
apy with platinum and etoposide should be considered, 
although prospective clinical trials do not provide 
evidence for the benefits of such management, sup-
ported only by extrapolation of the treatment results 
in small-cell lung carcinomas [177].
Palliative chemotherapy
The results of clinical studies involving patients with 
pancreatic NETs of G1 and G2 reported objective 
response rates range between 43–70% achieved with 
palitive chemotherapy,  [177, 225–228].
G1 and G2 NETs
Chemotherapy may be considered as the first-line treat-
ment in NENs of pancreatic origin with Ki-67 expression 
of 5–20% in the case of:
 — high tumor burden,
 — presence of clinical symptoms of the disease,
 — rapidly progressive disease (progression accor-
ding to radiological assessment RECIST < 6– 
–12 months),
 — neoadjuvant treatment to increase the resectability 
of a locally advanced lesion [177].
First-line treatment
The regimens using streptozocin and 5-fluorouracil 
(STZ/5FU) or STZ and doxorubicin as an alternative 
regimen (STZ/DOX) are acknowledged therapeutic 
options, considered to be a gold standard. The use 
of doxorubicin is limited by a cumulative dose of 
500 mg/m2, due to the risk of cardiotoxicity [225, 226]. 
Currently, streptozocin is not registered in Poland, and 
is not easily available.
*evidence level according to OCEMB [252]
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In such cases, an oral regimen with temozolomide 
and capecitabine (CAPTEM) can be used [177, 226].
It appears that a higher objective response rate fol-
lowing the use of temozolomide in pancreatic NENs 
may be correlated with expression of DNA-fixing 
enzyme — MGMT (O6-methylguanine DNA methyl-
transferase), which deficiency is more often observed in 
this location (approx. 50% of cases) [229–231]. However, 
determination of MGMT expression or methylation 
state is not currently recommended as a criterion for 
the use of chemotherapy.
Second-line treatment
After the failure of a first-line therapy, there are alterna-
tive options of systemic treatment available for patients 
in good general condition:
 — in the case of STZ-based chemotherapy, the use of 
temozolomide ± capecitabine (CAPTEM) should be 
considered [226];
 — in the case of CAPTEM regiment (due to limited 
availability of STZ), chemotherapy with oxaliplatin 
+ 5-FU or capecitabine (FOLFOX, XELOX) may be 
considered [232, 233].
G3 NETs and NECs
Chemotherapy is the standard therapy of palliative 
treatment in advanced, poorly differentiated NECs.
a) Pancreatic NECs with Ki 67 > 55%
The standard management involves chemotherapy 
with PE (cisplatin + etoposide) or CE (carboplatin + 
etoposide) regimen. According to the results of the 
NORDIC NEC study, cisplatin might be replaced  by 
carboplatin [234].
b) G3 NETs with Ki 67 < 55%
In the case of pancreatic G3 NETs (well-differentiated 
and moderately differentiated tumours with Ki-67 
> 20%, distinguished as a separate group in the new 
AJCC 2017 classification) or gastro-entero-pancreatic 
NECs with Ki-67 < 55%, temozolomide + capecitabine 
(CAPTEM) or streptozocin with 5-fluorouracil (STZ + 
5FU) chemotherapy should be preferably used [235, 236].
Second-line chemotherapy may be considered indi-
vidually, exclusively in patients with good performance 
status [177].
Topotecan should not be used as it appears to be 
ineffective in therapy of NECs [235].
Regimens based on oxaliplatin (FOLFOX, XELOX), 
temozolomide (CAPTEM), or irinotecan (FOLFIRI, IP) 
are recommended [236–238].
In the case of a good response to the first-line 
chemotherapy, maintained for at least three months 
after completion of the treatment, and without therapy-
related toxicity (e.g. neurotoxicity, ototoxicity, or renal 
failure), reinduction according to the PE/CE regimen 
may be considered.
Minimal consensus statement on chemotherapy
 — Advanced pancreatic NET of G1/2 — individualised treat-
ment, depending on the proliferation fraction and disease 
symptoms; chemotherapy is not the standard first-line 
therapy (in patients with Ki67 < 10% treatment with 
SSAs [lanreotide, evidence level 2b] or targeted drugs 
— everolimus or sunitinib [*evidence level 1b]). If the 
disease progresses rapidly threatens organ sufficiency, or 
symptoms occur, chemotherapy should be considered as the 
first-line treatment using a two-drug regimen, optimally 
based on streptozocin (*evidence level 2b). Currently, the 
medication is unavailable in Poland; therefore, an alterna-
tive regimen based on temozolomide + capecitabine may 
be considered (CAPTEM).
 — The basic treatment of pancreatic NECs involves cis-
platin and etoposide-based chemotherapy (*evidence 
level 3) as the first-line treatment, in particular with 
a high proliferation index Ki-67 > 55%. In the case of 
G3 NETs and NECs (Ki 67 < 55%) — STZ ± 5-Fu ± 
ADM chemotherapy may be considered, or alternatively, 
capecitabine and temozolomide (CAPTEM).
Minimal consensus statement on systemic therapies 
in pancreatic NENs:
Functional NETs of G1/G2 — SSA (*evidence level 1), 
and if the disease progresses, introduction of everolimus 
(*evidence level 1).
Non-functional, advanced NET of G1/G2 – SSA (oc-
treotide *evidence level 2, lanreotide, *evidence level 1) in 
the case of Ki67 < 10%, and if the disease threatens organ 
sufficiency, or is associated with pronounced symptoms, 
chemotherapy (optimally based on streptozocin combined 
with another medication, e.g. 5-FU, primarily in patients 
with G2 NET, or an alternative regimen: capecitabine and 
temozolomide) (*evidence level 3), or targeted treatment 
(everolimus or sunitinib, primarily in G1 patients, *evi-
dence level 1).
The basic NEC treatment involves chemotherapy based 
on cisplatin and etoposide, and, in the case of progression or 
resistance to therapy, a regimen based on 5-fluorouracil and 
temozolomide derivatives (*evidence level 3).
3.4. Radioisotope treatment
Radioisotope therapy with labelled somatostatine ana-
logues (PRRT, peptide receptor radionuclide therapy) 
is now one of the recognised forms of treatment, with 
an opportunity for the stabilisation or partial regression 
of the neoplastic disease, and less often for a complete 
remission [6, 239, 240]. The clinical data assessing the 
effectiveness of the therapy, including in PNETs, are cu-
mulating with every passing year, which was reflected 
in the recently published ENETS guidelines, as well 
*evidence level according to OCEMB [252]
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as in the European Association of Nuclear Medicine 
(EANM) guidelines [195, 241].
The recent ENETS guidelines regarding the use of 
various therapeutic forms as the first-line, second-line, 
and third-line therapies are based on studies published 
after 2012 (results of large, phase III clinical studies, 
i.e. PROMID, CLARINET, RADIANT-4, NETTER-1, 
TELESTRA, and SPINET). Unfortunately, there are 
no results of prospective studies using PRRT in pan-
creatic NETs available yet; in some published studies 
on the effectiveness of PRRT in this group of patients, 
the observed PFS is 29.7–39 months, and OS is 53–70 
months [242–245].
PRRT is recommended in G1/G2 tumours after 
a failure of treatment with SSA, chemotherapy, or 
molecular targeted therapies. Earlier use of PRRT in 
a selected group of patients is considered to be justi-
fied, and similarly to GEP NETs in different locations, 
the therapy can be used without previous chemother-
apy. In patients treated with chemotherapy before the 
radioisotope treatment, myelotoxicity and nephrotoxic-
ity occur more often.
Based on the NETTER-1 study (177Lu-DOTATATE vs. 
octreotide), ENETS recommends using PRRT as a sec-
ond-line treatment in midgut neoplasms, after a failure 
of pharmacological treatment. PRRT in pancreatic NETs 
is considered to be a second- or third-line treatment.
The choice between different therapeutic options 
in pancreatic NETs, in particular regarding PRRT, also 
depends on their availability in a given country, and the 
decision and experience of the attending physician, as 
well as the choice/approval of the patient.
Similarly to other GEP NETs, the main indications for 
PRRT in the treatment of pancreatic NETs are advanced, 
inoperable G2 or G1 tumours. In individual cases, the 
treatment may be considered in PNETs of G3 with 
high expression of somatostatin receptors, especially in 
a progressing disease, when other therapeutic options 
have been exhausted [6, 8, 9]. Eligibility for PRRT treat-
ment is in accordance with the principles described in 
the general section.
PRRT may also be considered as a neoadjuvant 
treatment in tumours inoperable due to a significant 
local advancement [6, 246]. Radiolabelled with 90Y and 
177Lu somatostatine analogues were used in PNET 
as a neoadjuvant therapy. Among the patients who 
received PRRT as a neoadjuvant therapy for an inop-
erable primary tumour, there were individual cases of 
patients with hepatic metastases, who demonstrated 
not only tumour regression but also regression of the 
meta lesions after the radioisotope therapy [247]. Due 
to the small group of patients in whom this form of 
treatment was used there is no evidence supporting 
introduction of PRRT before a non-surgical procedure 
to the management guidelines. However, this form of 
therapy may be considered individually, depending 
on the patient’s clinical condition, disease stage, and 
the proliferation index of the neoplasm.
In the case of functional pancreatic NETs, radio-
isotope treatment is possible as a palliative therapy 
to reduce the symptoms of hormone secretion [6, 23, 
135]. Based on individual reports in the literature, it 
is known that gastrinomas respond to therapy faster, 
but early progression is relatively frequent [6]. PRRT 
treatment may improve the control of hypoglycaemia 
in patients with malignant insulin-secreting tumours 
[74, 148, 248, 249].
PRRT may also be repeated during the subsequent 
progression of the disease, if stabilisation or remission 
was previously obtained with this method. It appeared 
that re-implementation of radioisotope treatment if 
somatostatin receptor expression is maintained by the 
tumour cells may prolong the patient’s survival without 
significant exacerbation of the adverse reactions associ-
ated with this therapy [250].
Radioisotope therapy is increasingly often combined 
with “cold” SSAs (also in the case of non-functional 
tumours).
Among different forms of radioisotope treatment in 
NETs, including PNETs, radioembolisation of hepatic 
metastases with yttrium-labelled microspheres is used 
[142, 251]. Since there are no reports on the use of ra-
dioembolisation in a larger group of patients, further 
studies in this field are necessary.
Place of radioisotope treatment in pancreatic NETs
Both in functional and non-functional PNETs, the basic 
form of treatment is surgery. In the case of functional 
pancreatic neoplasms, patients require additional ther-
apy due to the presence of clinical symptoms.
In the case of advanced pancreatic NETs, treatment 
with long-acting SSAs is recommended as the first-line 
therapy. According to the CLARINET study results, they 
should be used primarily in tumours with Ki-67 of up 
to 10%. PRRT should be considered as the second-line 
treatment alternative to tyrosine kinase inhibitors/ 
/chemotherapy. PRRT as the first-line treatment can be 
used in malignant insulin-secreting tumours, following 
symptomatic therapy other than SSAs.
Chemotherapy may be introduced as the later-line 
treatment if the disease progresses, especially when 
SSTR expression is lost, or as the second-line treatment, 
depending on the centre’s decision and experience of 
in the treatment of pancreatic G2 tumours.
The optimal treatment sequence may be established 
after the results of prospective studies are obtained.
*evidence level according to OCEMB [252]
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PRRT may be used in individual cases of pancreatic 
G3 NETs if a high expression of somatostatin receptors 
is confirmed and other forms of therapy are ineffective 
(*evidence level 4).
Minimal consensus statement on radioisotope thera-
pies in pancreatic NENs
Radioisotope therapy may be used in advanced, inoperable 
pancreatic NETs, especially G2 and G1, with the high soma-
tostatin receptor expression confirmed in SRI examination 
(*evidence level 3).
Qualification for PRRT: as in the general section of the 
guidelines.
PRRT is recommended after a failure of pharmacotherapy 
with SSAs.
PRRT may be considered as the second-line treatment, 
alternative to therapy with tyrosine kinase inhibitors.
4. Follow-up
The principles of treatment follow-up are the same 
as in GEP NENs, and have been discussed in detail 
in Diagnostic and therapeutic guidelines for gastro-entero- 
-pancreatic neuroendocrine neoplasms (recommended by the 
Polish Network of Neuroendocrine Tumours).
Minimal consensus statement on follow-up:
Monitoring of the treatment should be individualised 
according to histological differentiation of the NET (G1, G2, 
G3, or NEC) and the disease staging.
It comprises clinical examination, and determination of the 
concentration of CgA and specific markers (in functional tu-
mours, depending on the clinical symptoms), as well as USG, 
CT/MRI, endoscopic, and functional (SRI) examinations. The 
frequency of examinations depends on the stage of the disease 
(three months for NECs and 6–12 months for G1, G2, or G3 
NETs, or more frequently if disease progression is suspected).
The intervals in the follow-up may be extended if the 
disease is stabilised (especially in G1 NETs).
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